

This is a repository copy of *The hand-held fan and the Calming Hand for people with chronic breathlessness:a feasibility trial*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/143036/>

Version: Accepted Version

---

**Article:**

Swan, Flavia, English, Anne, Allgar, Victoria orcid.org/0000-0002-5228-2623 et al. (2 more authors) (2019) The hand-held fan and the Calming Hand for people with chronic breathlessness:a feasibility trial. Journal of pain and symptom management. ISSN 0885-3924

<https://doi.org/10.1016/j.jpainsymman.2019.02.017>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

# Palliative Medicine

## Facial airflow relieves chronic breathlessness in people with advanced disease: an exploratory systematic review and meta-analyses.

Journal:	<i>Palliative Medicine</i>
Manuscript ID	PMJ-18-0327.R1
Manuscript Type:	Review Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Swan, Flavia; University of Hull, Wolfson Palliative Care Research Centre Newey, Alison; University Hospital of South Manchester NHS Foundation Trust Bland, Martin; University of York Allgar, Victoria; University of York, Hull York Medical School Booth, Sara; Cambridge University Hospitals NHS Foundation Trust, Palliative Medicine Bausewein, Claudia; University Hospital Munich, Department of Palliative Medicine Yorke, Janelle; University of Manchester, School of Nursing, Midwifery and Social Work Johnson, Miriam; University of Hull, Wolfson Palliative Care Research Centre
Keywords:	dyspnea, review, self-management, airflow
Abstract:	<p>Background: Chronic breathlessness is a neglected symptom of advanced diseases.</p> <p>Aim: To examine the effect of airflow for chronic breathlessness relief.</p> <p>Design: Exploratory systematic review and meta-analysis.</p> <p>Data sources: Medline, CINAHL, AMED and Cochrane databases were searched (1985 – 2018) for observational studies or randomised controlled trials of airflow as intervention or comparator. Selection against pre-defined inclusion criteria, quality-appraisal and data extraction were conducted by two independent reviewers with access to a third for unresolved differences. "Before and after" breathlessness measures from airflow arms were analysed. Meta-analysis was carried out where possible.</p> <p>Results: 16/78 studies (n=929) were included; 11 randomised controlled trials of oxygen vs medical air, four randomised controlled trials and one fan cohort study. Three meta-analyses were possible: i) Fan at rest in three studies (n=111) offered significant benefit for breathlessness intensity (0-100mm Visual Analogue Scale and 0- 10 Numerical Rating Scale), mean difference -11.17 (95% confidence intervals -16.60 to -5.74), p=0.06 I<sup>2</sup> 64%. ii) Medical air via nasal cannulae at rest in two studies (n=89) improved breathlessness intensity (visual analogue scale), mean difference -12.0mm, 95% confidence intervals -7.4 to -</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	<p>16.6, <math>P &lt; 0.0001</math> <math>I^2 = 0\%</math>. iii) Medical airflow during a constant load exercise test before and after rehabilitation (n=29) in two studies improved breathlessness intensity (mBorg, 0-10) mean difference -2.9, 95% confidence intervals -3.2 to -2.7, <math>p &lt; 0.0001</math> <math>I^2 = 0\%</math>. Conclusion: Airflow appears to offer meaningful relief of chronic breathlessness and should be considered as an adjunct treatment in the management of breathlessness.</p>

SCHOLARONE™  
Manuscripts

1  
2  
3 **Airflow relieves chronic breathlessness in people with advanced disease: an exploratory**  
4 **systematic review and meta-analyses.**  
5  
6  
7

8 Flavia Swan, Wolfson Palliative Care Research Centre, Institute for Clinical and Applied Health  
9 Research, Allam Medical Building, Hull York Medical School (HYMS), University of Hull,  
10 Cottingham Rd, Hull, HU6 7RX  
11  
12  
13

14 Alison Newey, Community Palliative Care, University Hospital of South Manchester NHS  
15 Foundation Trust, Withington Community Hospital, Nell Lane, Manchester, M20 2LR  
16  
17  
18

19 Martin Bland, Department of Health Sciences, Seebohm Rowntree Building, University of York,  
20 Heslington, York YO10 5DD  
21  
22

23 Victoria Allgar, Department of Health sciences, University of York, Heslington, York YO10 5DD  
24  
25

26 Sara Booth, Associate Lecturer, Department of Oncology, University of Cambridge, Cambridge CB2  
27 0QQ  
28  
29

30  
31 Claudia Bausewein, Department of Palliative Medicine, Munich University Hospital,  
32 Marchioninstr. 15, 81377 München, Germany  
33  
34  
35

36 Janelle Yorke, School of Health Sciences, Division Nursing, Midwifery and Social Work, University  
37 of Manchester. Room 5.320, Jean McFarlane University, University Place, Oxford Road, Manchester  
38 M13 9PL and Christie Patient Centred Research group (CPCR) The Christie NHS Foundation Trust,  
39 Manchester.  
40  
41  
42

43  
44 Miriam Johnson, Wolfson Palliative Care Research Centre, Institute for Clinical and Applied Health  
45 Research, Allam Medical Building, Hull York Medical School (HYMS), University of Hull,  
46 Cottingham Rd, Hull, HU6 7RX  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Background: Chronic breathlessness is a neglected symptom of advanced diseases.

Aim: To examine the effect of airflow for chronic breathlessness relief.

Design: Exploratory systematic review and meta-analysis.

Data sources: Medline, CINAHL, AMED and Cochrane databases were searched (1985 – 2018) for observational studies or randomised controlled trials of airflow as intervention or comparator. Selection against pre-defined inclusion criteria, quality-appraisal and data extraction were conducted by two independent reviewers with access to a third for unresolved differences. “Before and after” breathlessness measures from airflow arms were analysed. Meta-analysis was carried out where possible.

Results: 16/78 studies (n=929) were included; 11 randomised controlled trials of oxygen vs medical air, four randomised controlled trials and one fan cohort study. Three meta-analyses were possible: i) Fan at rest in three studies (n=111) offered significant benefit for breathlessness intensity (0-100mm Visual Analogue Scale and 0- 10 Numerical Rating Scale), mean difference -11.17 (95% confidence intervals -16.60 to -5.74), p=0.06 I<sup>2</sup> 64%. ii) Medical air *via* nasal cannulae at rest in two studies (n=89) improved breathlessness intensity (visual analogue scale), mean difference -12.0mm, 95% confidence intervals -7.4 to -16.6, P<0.0001 I<sup>2</sup> =0%. iii) Medical airflow during a constant load exercise test before and after rehabilitation (n=29) in two studies improved breathlessness intensity (mBorg, 0-10) mean difference -2.9, 95% confidence intervals -3.2 to -2.7, p<0.0001 I<sup>2</sup> =0%.

Conclusion: Airflow appears to offer meaningful relief of chronic breathlessness and should be considered as an adjunct treatment in the management of breathlessness.

## Keywords:

- dyspnea,
- self-management,
- review,
- airflow (relevant term as the intervention subject heading)

### What is already known?

- Randomised Controlled Trials (RCTs) and cohort data have demonstrated that airflow delivered from the fan at rest offers significant relief of breathlessness.
- Systematic review (SR) and RCTs of oxygen vs medical air have failed to demonstrate additional benefit from oxygen therapy and suggest that medical air delivery, airflow, is likely to be an active intervention.
- All current evidence available for the effect of airflow for chronic breathlessness relief has not been explored using SR methods.

### What this paper adds

This exploratory SR and meta-analyses provide promising data to suggest that:

- airflow from the fan at rest improves breathlessness in people with breathlessness due to a variety of causes
- airflow delivered as cylinder medical air at rest improves breathlessness in advanced cancer
- airflow delivered as cylinder medical air during a constant load exercise test in people with chronic obstructive pulmonary disease and who have completed pulmonary rehabilitation

### Implications for practice and theory

- Clinicians should consider the fan as an adjunct to treatment for breathlessness at rest in patients who do not require oxygen-enriched air.
- Airflow may benefit exertion-induced breathlessness, but further work is required to investigate the role of the fan with everyday general activity and in relation to exercise.
- Recovery time from exertion-induced breathlessness, self-efficacy and daily activity are key outcomes to explore in future studies of airflow.

## Introduction

Breathlessness is a common, often poorly managed symptom in people with advanced diseases. It is associated with reduced quality of life (1), decreased activities of daily living (2), unplanned emergency hospital attendance and admission. (3-5) Breathlessness inflicts devastating and disabling physical, psychological and social burden on normal daily life for the patient, carers and close family members (6-8). Chronic breathlessness, that is, breathlessness that persists despite optimal treatment for the underlying pathophysiology and causing such disability (9), all too often is left for patients to manage themselves despite a developing evidence base for interventions targeted at the breathlessness itself.

Growing evidence supports complex non-pharmacological interventions to reduce the impact of the symptom and improve quality of life. (10-12) Components target peripheral and central afferent sources of breathlessness sensation, such as facial airflow delivered by the battery-operated hand-held fan (fan). (13-17) Cooling of the facial skin innervated by the 2<sup>nd</sup> and 3<sup>rd</sup> branches of the trigeminal nerve, nasal mucosae or the upper airway flow receptors could modulate the central perception of breathlessness leading to decreased neural respiratory drive, thereby reducing the sensation of breathlessness. (18-22) A recent multi-methods secondary analysis of qualitative interview data from three studies found that 80/111 (72%) participants experienced benefit when the fan was used in conjunction with other components of a complex intervention. (23) Airflow delivered from the fan may offer a valuable contribution to the self-management of chronic breathlessness (13, 15, 23), and has been identified as a potentially useful strategy in a variety of situations, e.g. breathlessness crisis (24), a component of pulmonary rehabilitation to assist recovery from exercise, or with general everyday activities. (15)

Systematic reviews (SR) of oxygen in a variety of non-hypoxic patient groups (cancer, chronic heart failure, kyphoscoliosis, COPD and ILD) have not demonstrated additional benefit from oxygen therapy over medical air delivery. (25-30) An updated Cochrane review of COPD found low quality evidence for modest relief of breathlessness. (31) The results from a large, adequately powered trial that randomised 239 participants (COPD 63%, cancer 16%) to receive at least 15 hours a day of oxygen or medical air delivered via home concentrator for seven days reaffirms earlier suggestion that medical air used in the placebo arm may not be an inert comparator as previously thought and points to the likelihood of an

1  
2  
3 active intervention. (29, 32) Therefore the placebo arm of oxygen studies may provide useful  
4 preliminary data regarding the role of airflow for the relief of chronic breathlessness. This  
5 systematic review aims to identify and evaluate data from studies of airflow, both from  
6 studies of the hand-held fan and the comparator arm data for breathlessness intensity from  
7 oxygen studies, analysed as “before and after” airflow exposure cohort data.  
8  
9  
10  
11  
12

### 13 **Aim**

14  
15  
16 To examine the current evidence for the effectiveness of airflow for the relief of chronic  
17 breathlessness.  
18  
19

### 20 **Methods**

21  
22  
23 The SR methods employed an exploratory approach in that only the airflow arm of studies  
24 were used and the data analysed as cohort “before and after” treatment.  
25  
26  
27  
28

### 29 **Study design**

30  
31  
32 The search methods employed are adapted from the Cochrane Handbook of Systematic  
33 Reviews (33) and reported in accordance with the Preferred Reporting Items for Systematic  
34 Reviews and Meta-Analyses (PRISMA). (34) A review protocol is not pre-registered but  
35 available from the University of Hull Library (Flavia Swan PhD Thesis).  
36  
37  
38  
39  
40

### 41 **Inclusion and exclusion criteria**

#### 42 **Types of studies**

43  
44  
45 Randomised Controlled Trials (RCTs), controlled clinical trials (quasi-randomised  
46 experimental trials with or without blinding) and observational cohort studies were included.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Types of participants

Adults with chronic breathlessness from any advanced disease aetiology as shown below:

- Malignancy: advanced primary and metastatic cancer patients, who have undergone disease treatments like chemotherapy, radiotherapy or surgical interventions.
- Chronic Obstructive Pulmonary Disease (COPD) with forced expiratory volume in 1 second (FEV<sub>1</sub>) of less than 50% predicted value
- Interstitial lung disease or pulmonary fibrosis where breathlessness is present
- Chronic heart failure: New York Heart Association (NYHA) stage III-IV
- Motor Neurone disease and other neurological disease where breathlessness is present or forced vital capacity (FVC) less than 80% predicted value
- Kyphoscoliosis: a moderate - severe sideways and forwards curvature of the spine Cobb Angle > 50° and FEV<sub>1</sub> of less than 50% predicted value.

Studies were included if at least 50% of the study population were classified as advanced, palliative or in the later stages of disease as defined above. These criteria were adapted from the Cochrane review of non-pharmacological interventions for breathlessness. (35)

Studies of participants with mild hypo or normoxaemia, who do not fore-fill the criteria for Long term Oxygen Therapy (LTOT) (36) were included. Studies of hypoxic participants or patients with any condition not assessed as progressive, refractory to treatment and advanced such as asthma were excluded.

## Types of exposure

Airflow: i) delivered from either a fan (hand-held or table) or non-oxygen enriched compressed air, or from a non-invasive ventilatory method (nasal cannula, mask or mouthpiece), but not Nasal Intermittent Positive Pressure Ventilation (NIPPV) and ii) directed at the cheek of the face, nasal mucosae or mouth.

Administration: as i) a single dose *during ambulation*, or *at rest* taken as needed (PRN *pro re nata*),(37) ii) placebo short-burst oxygen therapy (SBOT) intermittent use *before exercise* or

1  
2  
3 *after* exercise for recovery (36) or iii) continuously over 15hr a day as placebo long-term  
4 oxygen therapy (LTOT) studies or during the night as placebo nocturnal oxygen therapy  
5 (NOT studies) .(38)  
6  
7  
8  
9

10 Studies where airflow was directly administered to the trachea, or at sub-zero temperatures  
11 were excluded.  
12  
13

## 14 **Types of outcome measure**

### 15 **Unidimensional breathlessness outcomes**

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

ATS domains of dyspnea measurement (20) including breathlessness severity or intensity rated on uni-dimensional scales as shown below:

- Modified Borg Score, a categorical scale with ratio properties
- Visual Analogue Scale (VAS), 0 - 100mm anchored 0 = no shortness of breath and 100mm = shortness of breath as bad as can be
- Numerical Rating Scales (NRS), 0-10 numbered scale anchored 0 = Not breathless at all and 10 the worst imaginable breathlessness
- Likert scales with verbal responses such as “a bit better”, “much better” or “no difference” or any other validated uni-dimensional scale for measuring breathlessness.

Studies were only included if they reported the breathlessness outcome at baseline and post-treatment measured as either primary or secondary outcomes. If severity or intensity was measured as part of a multi-dimensional or composite scale, e.g. the Chronic Respiratory Questionnaire, that unidimensional measure of breathlessness was *not* extracted and analysed separately. Breathlessness related function/quality of life measures were *not* used as primary breathlessness outcomes in the absence of unidimensional scales.

## Other Outcomes

Other outcomes as shown below measured as either primary or secondary outcomes.

- Participant preference and satisfaction with the treatment
- Participant withdrawal and drop-out from the studies
- Adverse effects recorded

## Data sources and searches

Medline, CINAHL, AMED and Cochrane databases were searched (1985 – 2015; updated January 2018) for observational or randomised controlled trials (RCTs) of airflow as intervention *vs* control or as comparator *vs* oxygen. Reference lists were scanned. A full search strategy can be seen in Online Supplementary Table 1.

## Study selection

Titles, abstracts (and, where unclear, full papers) were screened against the eligibility criteria by two independent reviewers FS and AN, with recourse to MJ as a third reviewer in case of disagreement.

## Data extraction and synthesis

Baseline and post-intervention measures of breathlessness intensity were extracted from the fan studies and from the comparator arm of oxygen studies. Data were analysed as “before and after” airflow exposure cohort observational data.

## Risk of bias

FS and AN judged the reporting quality and internal validity for each of the included studies. The cohort study was evaluated according to the Cochrane guidelines for assessing bias in a non-randomised study. (39) As there is no tool that is applicable directly to the data extracted from the RCTs control arms, we assessed instead the quality of the parent RCTs as a proxy

1  
2  
3 marker for quality data. The RCTs were assessed with the Cochrane Risk of bias tool. (33)  
4 See online Supplementary Table 2.  
5  
6  
7

## 8 **Statistical Analysis**

9

10  
11 Results from the meta-analyses were reported for the primary outcome, breathlessness  
12 intensity or severity where heterogeneity allowed, or where not possible these were described  
13 narratively. NRS and VAS scales were combined by equating one point on a NRS scale to  
14 10mm on a VAS. (40, 41)  
15  
16  
17  
18


19  
20 Data calculations for mean difference and SD used STATA Version 12.1, Stata Corp LLC  
21 Texas 77845-4512, USA. Breathlessness measurements were analysed as continuous  
22 outcomes. Data from the placebo arm of cross-over RCTs were treated as single arm before-  
23 after studies. For studies that recorded median values, the mean were calculated from the  
24 extracted study data. (42) The  $I^2$  statistic was used to assess heterogeneity. (43) Where the  
25 result indicated significant heterogeneity a random effects model was chosen, otherwise a  
26 fixed effects model was applied. All analyses were undertaken on Review Manager 5.5. A  
27 sensitivity analysis was attempted for any study identified as including a sub-group not fitting  
28 the review criteria of mild hypo or normoxaemia to assess for any significant difference in  
29 the breathlessness outcome between the hypoxic and non-hypoxic participants.  
30  
31  
32  
33  
34  
35  
36  
37

## 38 **Results**

39

40  
41 A total of 403 records were identified for screening. After removal of duplicates, 78 records  
42 were reviewed. 14 abstracts were rejected for not meeting inclusion criteria; the remaining 64  
43 full text articles were assessed for eligibility. Of these, 16 studies met the review inclusion  
44 criteria and the other 48 studies were excluded (see Figure 1; PRISMA flow chart (34) and  
45 Online Supplementary Table 3, eAppendix).  
46  
47  
48  
49

50  
51 Overall studies represented 929 participants (age median 61.5, range 33 to 90 years; 47%  
52 men)  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1** PRISMA 2009 Flow-diagram of study selection and retrieval (34)

Airflow was delivered by fan (13, 14, 16, 17, 44) or as medical air. (29, 32, 45-53) See Table 1 for study characteristics

## Description of fan studies

**Design:** five studies (n=230) used the fan. Two feasibility RCTs; (n =49), (13) and (n=30), (44), a feasibility cohort study (n=31), (14), a feasibility longitudinal RCT (n=70), (16) and a phase III cross-over RCT (n=50), (17).

**Patient characteristics:** Four studies recruited a mixed population of people with breathlessness due to a variety of advanced conditions including COPD (n=101), cancer (n=55), heart failure (n=23) and other causes (n=21), (13, 14, 16, 17), and one study recruited advanced cancer only (n=30). (44)

**Intervention and comparator characteristics:** three studies used the fan to face at rest (14, 17, 44), two with comparator groups; fan to leg (17), or no fan use and carer support (44), and the other was a cohort design. (14) One study assessed acceptability of the fan when used with general activity over 6 months compared with an acupuncture wristband (16), and the remaining study assessed the fan when used with exercise advice over 4 weeks. (13)

**Breathlessness Outcome:** Three studies focused on the sensory-perceptual domain of dyspnea measurement and used breathlessness intensity as the primary outcome (17) or main outcome (14, 44). These studies selected the VAS (17), the NRS (44), or both VAS and NRS (14). The other two studies assessed symptom impact as well as the sensory-perceptual domain. These studies selected the NRS breathlessness intensity (13) and the Modified Borg Scale of breathlessness severity. (16)

**Other outcomes:** All of the fan studies reported participant withdrawals (13, 14, 16, 17, 44). These ranged from 0 to 6 participants. (13, 14, 44) One study reported that there were no Adverse Events (AE) (13) and the other fan studies did not include any AE details. (14, 16, 17, 44) Airflow preferences were described in four fan studies (13, 16, 17, 44) and not in one study. (14) In addition, one study quantified the experience of fan use at 2 months. (16)

## Description of medical air studies

**Design:** eleven RCT's (n=699) used oxygen, helium hyperoxia or both gases for the intervention compared with medical air. (29, 32, 45-53) Study size ranged from 16 to 239

1  
2  
3 participants. (29, 48) Four were cross-over (32, 48, 49, 51) and seven used a parallel group  
4 design. (29, 45-47, 50, 52, 53) Nine studies were double blind (29, 45-52), and two were  
5 single blind. (32, 53)  
6  
7  
8  
9

10 **Patient characteristics:** the eleven studies represent; COPD n=537, cancer n=109, other lung  
11 diseases n=21, cardiac disease n=14 and other causes n=18. Inclusion criteria required  
12 moderate to severe COPD (45-50, 52, 53), advanced cancer (51), or were a mixed population  
13 with no specific stipulation of severity. (29, 32)  
14  
15  
16  
17

18 **Intervention Characteristics:** the source of airflow was an oxygen cylinder (32, 45-50), a  
19 sham concentrator (29), and a Douglas bag. (52) Two studies did not state the airflow source.  
20 (51, 53) Medical air or compressed air was delivered through nasal cannulae (29, 32, 45, 47,  
21 49-51, 53), face-mask and nasal cannula (48), a non-rebreathing face-mask (46) and through  
22 a mouthpiece. (52) The flow rates varied widely in the studies; 2l/minute (29, 45), 3l/minute  
23 (47), 4l/minute (32, 49, 51), 5l/minute (53), 6l/minute (50) and 8l/minute *via* nasal cannula or  
24 15l/minute with face mask. (48) Two studies did not report flow rate details. (46, 52) The  
25 timing of airflow delivery was; 15 minutes at rest (32, 51), with daily activity over 3 (50), or  
26 6 months (45), 15 hours a day over one week (29), or in conjunction with exertion-induced  
27 breathlessness during pulmonary rehabilitation (PR), (46, 52, 53) or a walking test. (47-49)  
28 The PR programme parameters for airflow delivery were with treadmill exercise 3 times a  
29 week for 30 minutes over two months (53), a cycle ergometer used 3 times a week for 30  
30 minutes over 6 weeks (46), or 3 times a week for 20 minutes over two months. (52) The  
31 6MWT test parameters for airflow delivery were; i) three same day 6MWTs with 45 minutes  
32 washout, using room air for the basal walk and compressed air for the subsequent walks (47),  
33 ii) five 6MWTs performed over three visits, (timing not stated) using room air for the practice  
34 walk on visit one and cylinder air for the two 6MWTs with 60 minute washout on visits two  
35 and three (48), and iii) three same day 6MWTs using cylinder air with 20 minutes washout  
36 between tests at baseline, 6 and 12 weeks as well as short burst use at home with daily  
37 activity during the study period. (49)  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 **Breathlessness outcome:** two studies focused on the sensory-perceptual domain of dyspnea  
55 measurement and recorded breathlessness intensity as a primary outcome with the VAS and  
56 Borg scale (32) or the VAS only. (51) All of the other studies focused on symptom impact as  
57 well as the sensory-perceptual domain. (29, 45-50, 52, 53) Of these, three studies measured  
58  
59  
60

1  
2  
3 breathlessness intensity as a primary outcome with the NRS (29) or the CRQ dyspnea  
4 domain. (45, 50) The remaining six studies identified the modified Borg scale as one of the  
5 main outcomes (47-49, 52, 53) or a secondary measure. (46) One study in addition selected  
6 the CRQ. (49)  
7  
8  
9

10  
11 **Other outcomes:** participant withdrawals were reported in all of the studies (29, 32, 45-51,  
12 53), apart from one. (52) Five studies reported no withdrawals (32, 46-48, 51) and in the  
13 other five studies withdrawals ranged from 2 to 21 participants. (45, 53) AE were poorly  
14 reported with only two studies including details; “few” or “no AE”. (29, 46) All of the other  
15 studies omitted reporting AE. (32, 45, 47-53) Airflow preferences were only reported in one  
16 study. (51) The remaining studies did not report airflow preferences (29, 32, 45-48, 50, 52,  
17 53), although one study did quantify side-effects (29) and a second study examined  
18 preference for cylinder delivery of airflow. (50)  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1 Characteristics of included studies (fan)**

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, Adverse Events (AE), airflow preferences	Timing of measurement	Results airflow arm only (before and after treatment)	Improvement with airflow Yes/No
Booth (2016) [14]	Feasibility observational cohort	n= 31 Males: 20 Age mean: 74.8 SD 11.49  Mixed population, non-malignant, cardiorespiratory disease: 8 (26%)  Baseline dyspnoea score:  Mean VAS 48mm SD 27.4	Hand-held fan to face	No comparator group	Airflow from hand-held fan to face for 5 minutes	VAS (mm), NRS	Withdrawals = 6  AE and airflow preferences not reported	After 5 minutes at rest	VAS = Mean 35mm SD 25.7  after 5min air  Mean change = 12mm SD 21.2	Yes
Bausewein (2010) [16]	Feasibility longitudinal phase II RCT	n = 70 Males: 36 Age mean: 65.6yrs SD 8.80 COPD = 45, cancer = 25  Baseline dyspnoea score: 3.7 (1.83)	Hand-held fan to face	Wristband	Airflow from hand-held fan	Modified Borg score	Withdrawals at 2 months = 16/33 (48%)  AE not reported  Airflow preferences: Positive = 13/38 Negative = 7/38	Monthly over 6 months	Mean Borg score change over 2 months = 0.6 (SD 2.1 ), p = 0.90	No, phase II not powered to test
Galbraith (2010) [17]	Cross-over RCT	n = 50 Males: 23 Age mean: 71.3, range 33-90yrs  Mixed population; COPD = 26, lung cancer = 11, heart disease = 15  Baseline dyspnoea score:  VAS Fan/face 1st group = 31mm (SD 12-61mm)	Hand-held fan to face	Hand-held fan to leg	Airflow from hand-held fan to face for 5 minutes	VAS (mm)	Withdrawals = 1  AE not reported  Airflow preferences: positive patient comments, numbers not reported	After 5 minutes at rest and after 10 minute washout	VAS = -7.0mm Median change after 5 minutes Fan/face 1st group (IRQ 1.5 - 14.5)  VAS = -10.0mm Median change incl 10 minute washout Fan/face 1st group (IRQ 3.5 – 17), P=0.003	Yes

**Table 1 Characteristics of included studies (fan)**

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results: airflow arm only (before and after treatment)	Improvement with airflow Yes/No
Johnson (2016) [13]	Feasibility phase II RCT	n =49 Males: 26 Age mean: 68 (range 46-88) Mixed population; COPD = 28, cancer =9, heart disease = 5, others = 7 Baseline dyspnoea score Mean NRS = 5.7 (SD 1.5)	Hand-held fan to face at high or low flow rate	Usual care: verbal and written exercise and breathlessness management advice	Airflow from hand-held fan	NRS	Withdrawals = 6 No AE Airflow preference: positive patient comments, numbers not reported	After 4 weeks	NRS = 6.0 (2.0) at 4 weeks Mean change 0.0 (3.0)	No, phase II not powered to test
Wong (2017) [44]	Feasibility phase II RCT	n=30 Males: 14 Age: NR Lung cancer = 13, other cancers = 17 Baseline dyspnoea score Control group: NRS mean 5.6 (SD 1.55) Intervention group: NRS mean 6.13 (SD 2.48)	Table fan with low flow rate	Placebo accompanied by carer	Airflow from table fan to face for 5 minutes	NRS	No withdrawals AE not reported Airflow preference: mixed patient comments, numbers not reported	After 5 minutes at rest	NRS = 4.60 after 5 minutes fan to face Mean change -1.53 (1.06) p< 0.001	Yes

**Table 1 Characteristics of included studies (medical air)**

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results airflow arm only (before and after treatment)	Improvement with airflow Yes/No
Abernethy (2010) [29]	Double-blind RCT	n = 239 Males: 63% Age mean: Air = 74yrs (SD 10) Mixed: COPD = 152, Primary lung cancer = 33 Baseline dyspnoea score: Am air = 4.6 (SD 2.4) Pm air = 4.7 (SD 2.3)	Oxygen	Room air via concentrator	2l/min via nasal cannula for at least 15hrs a day (LTOT)	NRS 1-10	Withdrawals = 15 Few AE, number not reported Side-effects reported Airflow preferences not reported, oxygen only	Am and pm each day, within 30 minutes of waking and bedtime for 7 days	Am = -0.7 NRS point change Pm = -0.5 NRS point change, (p = 0.5)	Yes
Booth (1996) [32]	Single-blind cross-over RCT	n = 38 Males: 22 Age Median: 71 Range: 54-90yrs Lung Cancer 20, COPD 13, Cardiac 4 Baseline dyspnoea score: VAS 59mm	Oxygen	Cylinder air	4l/minute for 15 minutes via nasal cannula	VAS (mm) Modified Borg Scale	No withdrawals AE and airflow preferences not reported	After 15 minutes of breathing oxygen or air at rest.	VAS = -11mm change after air 48mm, p<0.001	Yes
Eaton (2006) [45]	Double-blind parallel RCT	n = 78 Males: 36 Age mean: 77.3yrs (7.06) Moderate/severe COPD Baseline CRQ score: Air = 17.5 (SD 4.2)	Oxygen	Cylinder air	2l/minute via nasal cannula over 6 months (SBOT)	CRQ	Withdrawals = 21 AE and airflow preferences not reported	Monthly over 6 months	CRQ = Average change over 6 months: air group = -3.6	No

**Table 1 Characteristics of included studies (medical air)**

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results airflow comparator arm only (before and after treatment)	Improvement with airflow Yes/No
Eves (2009) [46]	Double-blind RCT	n = 38 Males: 23 Age mean: 65.5yrs (SD 8) Stable COPD Baseline dyspnoea score: constant load exercise Borg mean: Air = 6.0 (SD 2.2) incremental load exercise Borg mean: Air = 5.6 (SD2.0)	Helium-hyperoxia (60% HE: 40% O <sup>2</sup> )	Cylinder air	Face mask (non-rebreathing)	Modified Borg score	No withdrawals No AE Airflow preferences not reported	During exercise test before and after 6 weeks pulmonary rehabilitation programme, 3 times a week for 30 minutes on cycle ergometer	constant load exercise Borg mean: Air = 4.2 (SD 2.1) mean change = -1.8 (95% CI -3.1 to -0.2), p < 0.05 incremental load exercise Borg mean: Air = 5.6 (SD 2.1) No change (95% CI -0.7 to 0.7)	Yes
Jolly (2001) [47]	Double-blind RCT	n = 20 Males: 19 Age mean: 68.5yrs (SEM 2.5) Stable COPD Baseline dyspnoea score: Borg mean score Desat group Baseline 6MWT = 5.82 (SEM 0.46) Non-desat group Baseline 6MWT = 4.22 (SEM 0.46)	Oxygen	Cylinder air	3l/minute via nasal cannula	Modified Borg score	No withdrawals AE and airflow preferences not reported	Before and after 3 x 6 MWTs with at least 45minutes washout between walks	Borg mean score: Desat group Air 6MWT = 5.82 (SEM 0.42) No change Non-desat group Air 6MWT = 4.44 (SEM 0.73) No change	No
Marciniuk (2007) [48]	Double-blind crossover RCT	n = 16 Males: 7 Age mean: 67 (SD 8) Moderate to severe COPD Baseline dyspnoea score: Borg mean score Baseline 6MWT = 5 (SD 2)	100% Oxygen or Helium-hyperoxia (70% HE: 30% O <sup>2</sup> )	Cylinder air	15l/minute via face mask 8l/minute via nasal cannula	Modified Borg score	No withdrawals AE and airflow preferences not reported	Before and after each 6 MWTs on visit 1,2 and 3 with 60 minutes washout between walks	Borg mean score After 6MWT Air = 3.5 mean Borg score change = -1.5 decrease	Yes

**Table 1 Characteristics of included studies (medical air)**

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results airflow comparator arm only (before and after treatment)	Improvement with airflow Yes/No
McDonald (1995) [49]	Double-blind crossover RCT	n = 26 Males: 24 Age mean: 73 (SD 6) Stable severe COPD Baseline dyspnoea score 6MWT: Air group = 3.8 (SD 1.4) CRQ = 14 (SD 5)	Oxygen	Cylinder air	4l/minute via nasal cannula	Modified Borg score CRQ	Withdrawals = 7 AE and airflow preferences not reported	After 6 and 12 weeks of home cylinder air using 6MWT exercise test with 20 minute washout between walks	Borg Mean score Home air: 6MWT with cylinder air = 3.8 (SD 1.5) No change CRQ score Home air = 17 (SD 6) 3 point change	No with 6MWT Yes with CRQ
Moore (2011) [50]	Double-blind RCT	n = 143 Males: 99 Age mean: 71.8yrs (SD 9.8) Range: 43-78 Stable COPD Baseline dyspnoea score: Air = 17.5 (SD 4.9)	Oxygen	Cylinder air	6l/minute via nasal cannula at home for 12 weeks with activity (SBOT)	CRQ	Withdrawals = 4 AE not reported Airflow preferences 45% prefer no cylinder	At 4 weeks and 12 weeks	Air: 4 weeks = 18.4 (SD 5.8) 12 weeks = 18.4 (SD 5.8) Air: CRQ = Mean change at 4 and 12 weeks = 0.9	Yes
Philip (2006) [51]	Double-blind cross-over RCT	n = 51 Males: 31 Age median: 65 Range: 33-82yrs NSCLC = 22, Small cell lung cancer = 6, Breast = 8, Colorectal = 4 Others = 11 Baseline dyspnoea score: VAS median Air 1st = 52mm (range 23-92) VAS median Air 2nd = 42mm (range 10-70)	Oxygen	Medical Air	4l/minute for 15 minutes via nasal cannula	VAS (mm)	No withdrawals AE not reported Airflow preferences: Positive: n=15 (29%)	Before and after 15 minutes of gas	VAS median After air 1st = -3mm change (range -19 to 7) VAS median After air 2nd = -11.5mm change (range -20 to 45) VAS mean change = -13.4mm	Yes

**Table 1 Characteristics of included studies (medical air)**

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results airflow comparator arm only (before and after treatment)	Improvement with airflow Yes/No
Scorsone (2010) [52]	Double-blind RCT	n = 30 Males: 23 Age mean: 67.3yrs (SD 8.3) Moderate to severe COPD Baseline dyspnoea score: Before training incremental load exercise Borg: Air = 7 (SD 3) Before training constant load exercise Borg: Air = 8 (SD 3)	40% Oxygen or Helium - hyperoxia (60% HE: 40% O <sup>2</sup> )	Humidified room air	Mouthpiece from a Douglas bag	Modified Borg score	No withdrawals AE and airflow preferences not reported	During exercise before and after a 2 months pulmonary rehabilitation programme, 3 times a week for 20 minutes on cycle ergometer	After training incremental load exercise Borg: Air = 4 (SD 2) After training constant load exercise Borg = 5 (SD 3) Borg change = -3 point decrease both exercise tests	Yes
Wadell (2001) [53]	Single-blind crossover RCT	n = 20 Males: 10 Age mean: 67yrs Range: 52-73 Stable COPD Baseline dyspnoea median score: Test A (Air) At rest; Pre-training Borg: Air group = 1.5 (0-3) Test A (Air) After 6MWT, Pre-training Borg: Air group = 6.5 (4-9)	Oxygen	Air	5l/minute via nasal cannula	Modified Borg score	Withdrawals =2 AE and patient preferences not reported	During exercise using 2 x 6MWT (air/O <sup>2</sup> or O <sup>2</sup> /air) with 1hour washout before and after a 2 months pulmonary rehabilitation programme, 3 times a week for 30 minutes on a treadmill	Test A (Air) At rest; Post-training Borg: Air group = 1 (0-3) Test A (Air) After 6MWT, Post-training Borg: Air group = 6 (1-7) Borg change = -0.5 point at rest and after exercise test	Yes

## Risk of Bias

The quality appraisal is summarised in Online Supplementary Table 2 and described below.

**Allocation:** all of the studies, apart from one, a cohort design (14), were described as RCTs. It was possible to verify the randomisation process in eight studies. (13, 16, 17, 29, 32, 45, 46, 50). There was insufficient information to determine the risk of allocation bias in the other RCTs. (44, 47-49, 51-53)

**Blinding:** two of the fan studies attempted to blind the participants (16, 17); a placebo wristband was used as a comparator (16) and participants were not told if the fan to face or fan to leg was the active intervention. (17) There was no blinding in two studies, a cohort and phase II RCT (13, 14), and the fifth study stated single blinding that could not be verified from the methods described. (44) All five were judged high risk of bias due to incomplete blinding or limited description. Nine medical air RCTs were described as double blind. (29, 45-52) All were judged low risk of bias (29, 45, 46, 48-50, 52), apart from one study that was unclear due to the lack of detail reported. (51) Two RCTs were single blind (32, 53); one was judged low risk of bias (32) and the other was regarded as unclear risk due to the inadequate description. (53)

**Incomplete outcome data:** 13 studies adequately addressed withdrawals and incomplete outcome data; these were considered low risk of bias. (13, 14, 17, 29, 32, 46-53) Three studies were uncertain risk (16, 45); one due to the proportion of attrition (16) and the other two lacked description of how any missing data were statistically managed. (44, 45)

**Selective Outcome reporting:** all of the studies reported the pre-specified outcomes and were judged as low risk of bias. (13, 14, 16, 17, 29, 32, 44-53) Study protocols were available for eight studies. (13, 14, 16, 17, 29, 46, 50, 51)

**Other issues of bias:** twelve studies appeared free from other bias and were judged low risk. (13, 16, 17, 29, 44-46, 48, 50-53) Three studies reported insufficient information to adequately assess risk (32, 47, 49), and one study, a cohort design was judged high risk. (14)

## Effect of interventions

The airflow was delivered, i) at rest (14, 17, 32, 44, 51) ii) over days or weeks (either intermittently or as periods of continuous flow) whilst the participant continued with usual general activities (13, 16, 29, 45, 50) or iii) during specific episodes of exertion induced breathlessness. (46-49, 52, 53)

### i) At rest

Five studies demonstrated improvement with airflow delivery at rest.

Results from 5 minutes fan use to the face in three studies were VAS breathlessness intensity difference from baseline mean -7mm (CI -11.5 to -2.5) (17), and mean -12mm (CI -19.3 to -4.4) (14), and for the NRS mean change -1.53 (-9.6 to -6.5).(44)

Cylinder medical air delivery for 15 minutes demonstrated improvement VAS breathlessness intensity mean -11mm (CI -17.0 to -5.0) (32), and mean -13mm (CI -20.5 to -6.3). (51) Four studies were sub-divided into two groups and included in meta-analyses.

### *Fan*

Airflow from the fan at rest improved breathlessness in a mixed population (n=111; 58% cancer) VAS (mm) mean difference (MD), -11.17 (CI -16.60 to -5.74), p=0.06. Significant heterogeneity was observed, Chi<sup>2</sup> p-value = 0.2, (I<sup>2</sup> = 64%) (See Figure 2).

<<insert Figure 2 Meta-analysis of fan at rest >>

### *Medical air*

Airflow delivered as cylinder medical air at rest improved breathlessness in advanced cancer (n=89) VAS (mm) MD -12.0, (CI -16.6 to -7.4), P<0.0001. No evidence of heterogeneity was observed, Chi<sup>2</sup> P value = 0.6, (I<sup>2</sup> =0%).

<<insert Figure 3 Meta-analysis of cylinder air at rest >>



## ii) General activity

Six studies used airflow at home with everyday general activity. A narrative description was used for these due to study diversity. Breathlessness points change from four cylinder air studies were mixed (29, 45, 49, 50), with CRQ -3.6 after 6 months (45), 3.0 after 12 weeks (49), or 0.9 at 12 weeks (50), or NRS -0.7 (am) and -0.5 NRS (pm) after 7 days. (29) In the two fan studies a modified Borg score of -0.6 (SD 2.1) was found after 2 months (16), but there was no NRS score change after 4 weeks of fan use with exercise advice. (13)

## iii) Exertion-induced breathlessness

Six studies examined airflow delivery with exertion-induced breathlessness. Results for mean Borg breathlessness score during a walking test for three studies varied; no change during a 6MWT repeated on the same day (47), or at 12 weeks (49), and improvement -1.5 for a 6MWT repeated on 3 separate visits. (48) Airflow delivered during a constant load exercise test after PR in three studies also demonstrated variable improvement in mean Borg breathlessness scores; -1.8 points (46), and -3 point (52) using a cycle ergometer, and -0.5 point from a treadmill test. (53) Two studies were suitable to include in a meta-analysis (See Figure 4). (46, 52)

### *Medical air*

Airflow delivered as cylinder medical air during a constant load exercise test after PR in COPD (n=29) significantly improved breathlessness Borg score MD -2.9, (CI -3.2 to -2.7),  $p < 0.0001$ . No evidence of heterogeneity was observed,  $\text{Chi}^2$  p-value = 0.7, ( $I^2 = 0\%$ ), (Figure 4).

<< insert Figure 4 Meta-analysis of cylinder medical air for exertion-induced breathlessness >>

## Discussion

These exploratory data support that facial and nasal airflow delivery at rest offers relief of breathlessness intensity consistent with a moderate clinically important difference, (54, 55) and during exertion. (46, 52) All participants in the cylinder medical air delivery at rest studies had advanced cancer, but nearly half of those in the fan “at rest” studies had other conditions indicating that airflow for breathlessness at rest is of benefit irrespective of cause.

In a recent pooled qualitative data study of facial airflow use from the fan in 133 people with chronic breathlessness (56), over 80% patients reported some or substantial benefit.(57) However, the data presented here varied with regard to relief of breathlessness intensity when facial or nasal airflow delivery was used with everyday general activity or with exertion induced breathlessness. This may reflect the use of outcome measures that do not reliably capture change in breathlessness intensity in the context of exertion. Studies that used a 6MWT (47-49) highlight the problem of a self-paced test that allows patients to control their walking speed and thus limit the maximal level of exertion–induced breathlessness experienced. In contrast, studies that used an externally paced test, such as the cycle ergometer, identified relief of breathlessness intensity. (46, 52) The relationship between exercise and breathlessness intensity is complex, and measuring one without taking the other into account may miss relevant improvement. Scores are likely to remain static after the introduction of an intervention as patients are able to exert themselves to the same level of breathlessness without noticing an increase in their exercise tolerance (58), or indeed the outcome may be of little value to the patient. (57)

A previous study of recovery time after an ISWT in people with thoracic cancer (n=57) reported a rapid reduction in breathlessness intensity with a return to baseline time of median 4 (IQR 2-5) minutes. (59) The analysis of 133 patient interviews found that a faster recovery time was a key patient-reported benefit of airflow delivered from the fan, irrespective of breathlessness intensity. (57) Even though recovery time may only be a matter of minutes, interventions which shorten this further are clearly welcomed and give the patient a sense of self-control that may help prevent a breathlessness-anxiety spiral. The ability to recover quickly and predictably from bouts of exertion is likely to encourage further activity and prevent the deconditioning cycle.

1  
2  
3 The fan therefore seems suitable as a patient-delivered intervention to target the recovery  
4 time from exertion-induced breathlessness. Preliminary magnetoencephalography (MEG)  
5 imaging data suggests airflow delivery during recovery from exercise may modulate central  
6 perception of breathlessness by modifying sensory attention. (60) Cooling of the facial skin  
7 innervated by the 2<sup>nd</sup> and 3<sup>rd</sup> branches of the trigeminal nerve and/or stimulation of nasal  
8 mucosa and upper airway ‘flow’ receptors are reported to improve breathlessness intensity  
9 and exercise tolerance (18, 19, 61, 62) and could “fool” the brain into thinking that the  
10 respiratory status is adequate. (22)  
11  
12

13  
14  
15  
16  
17  
18 Unpleasant respiratory sensations associated with exercise are known to adversely influence  
19 adherence to an exercise regime. (63) Therefore, use of airflow as part of PR may help the  
20 problems of low patient attendance and poor maintenance of long term outcomes. (64-67)  
21 Facial airflow from fan use during a cycle ergometer test in COPD patients resulted in  
22 significant breathlessness reduction and a longer total exercise time. (68) Likewise, the meta-  
23 analysis result from this SR suggest significant relief of breathlessness when airflow is  
24 delivered during exercise. These data highlight the potential value of using airflow delivery  
25 with PR or home based exercise programmes. In addition, intervention preference and AE  
26 data support the role of the fan in this context as a portable device that is unlikely to harm and  
27 therefore appropriate for the majority of patients to try.  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 Finally, it is likely that any positive benefits of airflow delivery from fan use with everyday  
38 general activity and at rest were not captured in the review data. The lack of signal from the  
39 results may in part reflect the complexity and the nuances of when, where and how this  
40 intervention is used by patients. (57) Current breathlessness management is modelled on a  
41 complex intervention, of which the fan is identified as a valuable therapeutic component  
42 alongside other interventions and strategies that are tailored to the patient’s breathlessness  
43 needs. (11, 69)  
44  
45  
46  
47  
48  
49  
50

### 51 **Limitation of methods**

52  
53

54 Data were analysed as cohort “before and after” design, and no adjustments were made to  
55 control for confounding bias. The pre-post comparison increases the potential risk of bias and  
56 it is possible that results may be influenced by the timing of “before and after” measures. For  
57 example, studies of longer duration (up to 6 months) may not be representative of the  
58  
59  
60

1  
2  
3 immediate benefits of airflow, but rather reflect more complex use and mechanism of any  
4 observed benefit may be related to reconditioning, facilitated by airflow, over time. Risk of  
5 bias was assessed using a tool designed for RCTs therefore it is possible that this assessment  
6 may not capture potential sources of bias associated with the observational methods used in  
7 this SR.  
8  
9  
10  
11  
12

13 Overall, the qualitative synthesis represents findings from 929 participants the largest to date,  
14 however the meta-analyses pertain to a small number of participants and only provide a  
15 preliminary indication of the pooled effect estimate of airflow. The meta-analyses involve  
16 few studies therefore heterogeneity is difficult to estimate and the accuracy of the  $I^2$  value is  
17 less certain. (70) The number of studies that fulfilled the review criteria was restricted by the  
18 need for baseline breathlessness measures. Some of the included studies (32, 51) did not  
19 report repeated measurements in a format suitable for meta-analysis necessitating statistical  
20 assumptions. (42)  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Implications for practice and further research**

30  
31 Airflow is safe and should be used as an adjunct to treatment for breathlessness at rest in  
32 those who do not require oxygen-enriched air. Clinicians should consider airflow an  
33 important intervention to use as part of a breathlessness management programme in  
34 breathlessness at rest irrespective of cause. The relief of breathlessness during exertion in  
35 those with COPD may provide a useful intervention during pulmonary rehabilitation where  
36 breathlessness is a reason for poor adherence.  
37  
38  
39  
40  
41  
42

43 The fan, when taught by an appropriately trained clinician, offers patients an inexpensive and  
44 portable source of airflow likely to benefit exertion-induced breathlessness. Recovery time  
45 from exertion induced breathlessness is an important patient-reported outcome and further  
46 work is needed to explore the role of airflow in recovery, self-efficacy and increased daily  
47 activity as part of complex breathlessness intervention programmes including rehabilitation.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusion

These data support facial or nasal airflow for clinically meaningful relief of breathlessness at rest. This SR pulls together the growing evidence to support airflow as an effective self-management option for people with chronic breathlessness and identifies airflow as an intervention for future study.

## Declarations.

**Authorship:** Concept - FS; Design - FS, MJJ, CB, SB, JY; Data collection - FS, AN; Data analysis - FS, VA, MB; Data interpretation- All; Draft manuscript FS; critical revision of manuscript for intellectual content – All; approval final manuscript – All.

**Funding:** This study was funded as part of a University of Hull PhD studentship (Flavia Swan)

**Declaration of conflicts of interest:** The Authors declare that there is no conflict of interest.

**Data management and sharing:** The full search strategy is found in the Online Supplementary materials and included and excluded papers are presented.

## References

1. Currow DC, Dal Grande E, Ferreira D, Johnson MJ, McCaffrey N, Ekström M. Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups. *Thorax*. 2017.
2. Smith AK, Currow DC, Abernethy AP, Johnson MJ, Miao Y, Boscardin WJ, et al. Prevalence and Outcomes of Breathlessness in Older Adults: A National Population Study. *Journal of the American Geriatrics Society*. 2016;64(10):2035-41.
3. Parshall MB. Adult Emergency Visits for Chronic Cardiorespiratory Disease: Does Dyspnea Matter? *Nurs Res*. 1999;48(2):62-70.
4. Parshall MB, Doherty GS. Predictors of emergency department visit disposition for patients with chronic obstructive pulmonary disease. *Heart & Lung: The Journal of Acute and Critical Care*. 35(5):342-50.
5. Hutchinson A, Pickering A, Williams P, Bland JM, Johnson MJ. Breathlessness and presentation to the emergency department: a survey and clinical record review. *BMC Pulmonary Medicine*. 2017;17:1-7.
6. Bausewein C, Booth S, Gysels M, Kuhnbach R, Haberland B, Higginson IJ. Understanding breathlessness: cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. *Journal of Palliative Medicine*. 2010;13(9):1109-18.
7. Booth S, Silvester S, Todd C. Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers. *Palliative & Supportive Care*. 2003;1(4):337-44.
8. Williams V, Bruton A, Ellis-Hill C, McPherson K. What really matters to patients living with chronic obstructive pulmonary disease? An exploratory study. *Chronic Respiratory Disease*. 2007;4(2):77-85.
9. Johnson MJ, Yorke J, Hansen-Flaschen J, Lansing R, Ekström M, Similowski T, et al. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. *European Respiratory Journal*. 2017;49(5).
10. Farquhar MC, Prevost AT, McCrone P, Brafman-Price B, Bentley A, Higginson IJ, et al. The clinical and cost effectiveness of a Breathlessness Intervention Service for patients with advanced non-malignant disease and their informal carers: mixed findings of a mixed method randomised controlled trial. *Trials*. 2016;17(1):1-16.
11. Higginson IJ, Bausewein C, Reilly CC, Gao W, Gysels M, Dzingina M, et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. *The Lancet Respiratory Medicine*. 2014;2(12):979-87.
12. Barton R EA, Nabb S, Rigby AS, and Johnson MJ A randomised trial of high Vs low intensity training in breathing techniques for breathless patients with malignant lung disease: A feasibility study. *Lung cancer* 2010;70:313-9.
13. Johnson MJ, Booth S, Currow DC, Lam LT, Phillips JL. A Mixed-Methods, Randomized, Controlled Feasibility Trial to Inform the Design of a Phase III Trial to Test the Effect of the Handheld Fan on Physical Activity and Carer Anxiety in Patients With Refractory Breathlessness. *Journal of Pain and Symptom Management*. 2016;51(5):807-15.
14. Booth S, Galbraith S, Ryan R, Parker RA, Johnson M. The importance of the feasibility study: Lessons from a study of the hand-held fan used to relieve dyspnea in people who are breathless at rest. *Palliative Medicine*. 2016;30(5):504-9.
15. Swan F BS. The role of airflow for the relief of chronic refractory breathlessness. . *Current Opinion in Supportive & Palliative Care* 2015;Sept 9(3):206-11.
16. Bausewein C BS, Gysels M, Kuhnbach R, and Higginson I J,. Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial. *BMC Palliative Care* 2010;9(22).

17. Galbraith S, Fagan P, Perkins P, Lynch A, Booth S. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. *Journal of Pain and Symptom Management* [Internet]. 2010; (5):[831-8 pp.].
18. Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold Facial Stimulation Reduces Breathlessness Induced in Normal Subjects. *American Journal of Respiratory and Critical Care Medicine*. 1987;136(1):58-61.
19. Liss HP GJ. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. *American Review Respiratory disease* 1988;137:1285-8.
20. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea. *American Journal of Respiratory and Critical Care Medicine*. 2012;185(4):435-52.
21. Johnson MJ, Simpson MIG, Currow DC, Millman RE, Hart SP, Green G. Magnetoencephalography to investigate central perception of exercise-induced breathlessness in people with chronic lung disease: a feasibility pilot. *BMJ Open*. 2015;5(6):e007535.
22. Morélot-Panzini C. Fooling the brain to alleviate dyspnoea. *European Respiratory Journal*. 2017;50(2).
23. Lockett T PJ, Johnson MJ, Farquhar M, Swan F, Assen T, Bhattarai P, Booth S. . Contributions of a hand-held fan to self-management of chronic breathlessness. . *European Respiratory Journal*. 2017;50(1700262).
24. Mularski R, Reinke L, al C-KVe. An official American Thoracic Society workshop report: Assessment and palliative management of dyspnea crisis. *Annals American Thoracic Society*. 2013;10(5):S98-105.
25. Ben-Aharon I, Gafter-Gvili A, Paul M, Leibovici L, Stemmer SM. Interventions for Alleviating Cancer-Related Dyspnea: A Systematic Review. *Journal of Clinical Oncology*. 2008;26(14):2396-404.
26. Booth S, Wade R, Johnson M, Kite S, Swannick M, Anderson H, et al. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. *Respiratory Medicine*. 2004;98(1):66-77.
27. Cranston Josephine M, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. *Cochrane Database of Systematic Reviews* [Internet]. 2008; (3).
28. Uronis HE, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. *Br J Cancer*. 2008;98(2):294-9.
29. Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE, 2nd, Marcello J, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. *Lancet*. 2010;376(9743):784-93.
30. Bell EC, Cox NS, Goh N, Glaspole I, Westall GP, Watson A, et al. Oxygen therapy for interstitial lung disease: a systematic review. *European Respiratory Review*. 2017;26(143).
31. Ekstrom M, Ahmadi Z, Bornefalk-Hermansson A, Abernethy A, Currow D. Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. *Cochrane Database of Systematic Reviews*. 2016;11:CD006429.
32. Booth S, Kelly MJ, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer? *American Journal of Respiratory and Critical Care Medicine*. 1996;153(5):1515-8.
33. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. 2011. In: *The Cochrane Collaboration* [Internet]. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org).
34. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement 2009 2009-07-21 10:46:49.
35. Bausewein C, Booth S, Gysels M, Higginson Irene J. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. *Cochrane Database of Systematic Reviews* [Internet]. 2008; (2).



- 1
- 2
- 3
- 4 36. Royal College of Physicians. Domiciliary oxygen therapy services: clinical guidelines and
- 5 advice for prescribers. A report of the Royal College of Physicians. London: Royal College of
- 6 Physicians; 1999.
- 7 37. Uronis H, McCrory Douglas C, Samsa G, Currow D, Abernethy A. Symptomatic oxygen for
- 8 non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews
- 9 [Internet]. 2011; (6).
- 10 38. Report of the medical research council working party. Long term domiciliary oxygen in
- 11 chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *Lancet*. 1981;1:681-
- 12 6.
- 13 39. Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies
- 14 2008.
- 15 40. Powers J, Bennett S. Measurement of dyspnea in patients treated with mechanical
- 16 ventilation. *American Journal of Critical Care*. 1999;8(4):254-61.
- 17 41. Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies
- 18 comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment
- 19 of pain intensity in adults: a systematic literature review. *J Pain Symptom Manage*. 2011;41(6):1073-
- 20 93.
- 21 42. Hozo S, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range,
- 22 and the size of a sample. *BMC Medical Research Methodology*. 2005;5(1):13.
- 23 43. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses
- 24 *The Cochrane Collaboration*, ; 2011. .
- 25 44. Wong SL, Leong SM, Chan CM, Kan SP, Cheng HW. The Effect of Using an Electric Fan on
- 26 Dyspnea in Chinese Patients With Terminal Cancer. *American Journal of Hospice & Palliative*
- 27 *Medicine*.34(1):42-6.
- 28 45. Eaton T, Fergusson W, Kolbe J, Lewis CA, West T. Short-burst oxygen therapy for COPD
- 29 patients: a 6-month randomised, controlled study. *European Respiratory Journal*. 2006;27(4):697-
- 30 704.
- 31 46. Eves ND, Sandmeyer LC, Wong EY, Jones LW, Macdonald GF, Ford GT, et al. Helium-
- 32 Hyperoxia: A Novel Intervention To Improve the Benefits of Pulmonary Rehabilitation for Patients
- 33 With COPD. *Chest*. 2009;135(3):609-18.
- 34 47. Jolly EC, Di Boscio V, Aguirre L, Luna CM, Berensztein S, Gené RJ. Effects of Supplemental
- 35 Oxygen During Activity in Patients With Advanced COPD Without Severe Resting Hypoxemia. *Chest*.
- 36 2001;120(2):437-43.
- 37 48. Marciniuk DD, Butcher SJ, Reid JK, MacDonald GF, Eves ND, Clemens R, et al. The Effects of
- 38 Helium-Hyperoxia on 6-mm Walking Distance in COPD: A Randomized, Controlled Trial. *CHEST*.
- 39 2007;131(6):1659-65.
- 40 49. McDonald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE. Exertional oxygen of limited
- 41 benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. *American*
- 42 *Journal of Respiratory and Critical Care Medicine* [Internet]. 1995; (5 Pt 1):[1616-9 pp.].
- 43 50. Moore RP, Berlowitz DJ, Denehy L, Pretto JJ, Brazzale DJ, Sharpe K, et al. A randomised trial
- 44 of domiciliary, ambulatory oxygen in patients with COPD and dyspnoea but without resting
- 45 hypoxaemia. *Thorax* [Internet]. 2011; (1):[32-7 pp.].
- 46 51. Philip J, Gold M, Milner A, Di Iulio J, Miller B, Spruyt O. A Randomized, Double-Blind,
- 47 Crossover Trial of the Effect of Oxygen on Dyspnea in Patients with Advanced Cancer. *Journal of Pain*
- 48 *and Symptom Management*. 2006;32(6):541-50.
- 49 52. Scorsone D, Bartolini S, Saporiti R, Braido F, Baroffio M, Pellegrino R, et al. Does a Low-
- 50 Density Gas Mixture or Oxygen Supplementation Improve Exercise Training in COPD? *Chest*.
- 51 2010;138(5):1133-9.
- 52 53. Wadell K, Henriksson-Larsen K, Lundgren R. Physical training with and without oxygen in
- 53 patients with chronic obstructive pulmonary disease and exercise-induced hypoxaemia. *Journal of*
- 54 *rehabilitation medicine*. 2001;33(5):200-5.
- 55
- 56
- 57
- 58
- 59
- 60



- 1
- 2
- 3
- 4 54. Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC. Clinically Important
- 5 Differences in the Intensity of Chronic Refractory Breathlessness. *Journal of Pain and Symptom*
- 6 *Management*. 2013;46(6):957-63.
- 7 55. Ries A. Minimally clinically important difference for the UCSD Shortness of Breath
- 8 Questionnaire, Borg Scale, and Visual Analog Scale. *Journal of Chronic Obstructive Pulmonary*
- 9 *Disease*. 2005;2:105-10.
- 10 56. Johnson MJ YJ, Hansen-Flaschen J, Lansing R, Ekstrom M, Similowski T, Currow D. . Towards
- 11 an expert consensus to delineate a clinical syndrome of chronic breathlessness. . *European*
- 12 *Respiratory Journal* 2017.
- 13 57. Lockett T, Phillips J, Johnson MJ, Farquhar M, Swan F, Assen T, et al. Contributions of a hand-
- 14 held fan to self-management of chronic breathlessness. *European Respiratory Journal*. 2017;50(2).
- 15 58. Currow DC, Abernethy AP, Johnson MJ. Activity as a Measure of Symptom Control. *Journal of*
- 16 *Pain and Symptom Management*. 2012;44(5):e1-e2.
- 17 59. Maddocks M, Taylor V, Klezlova R, England R, Manderson C, Wilcock A. When will I get my
- 18 breath back? Recovery time of exercise-induced breathlessness in patients with thoracic cancer.
- 19 *Lung cancer*. 2012;76(1):128-9.
- 20 60. Johnson MJ, Simpson M, Millman R, Green G. Magnetoencephalography as a neuro-imaging
- 21 method in chronic dyspnoea: A feasibility study. *European Respiratory Journal*. 2014;44(Suppl.
- 22 58):P670.
- 23 61. Baltzan MA, Alter A, Rotaple M, Kamel H, Wolkove N. Fan to palliative exercise-induced
- 24 dyspnoea with severe COPD. *Journal of respiratory and critical care medicine*. 2000;161(3
- 25 supplement):A59.
- 26 62. Marchetti N, Travaline J, Criner G. Air current applied to the face of COPD patients enhances
- 27 leg ergometry performance. *Am J Resp and Crit Care*. 2004;169:A773.
- 28 63. Resnick B SA. Understanding what motivates older adults to exercise *Journal of*
- 29 *gerontological nursing*. 2000;26(3):34-41.
- 30 64. Keating A, Lee A, Holland AE. What prevents people with chronic obstructive pulmonary
- 31 disease from attending pulmonary rehabilitation? A systematic review. *Chronic Respiratory Disease*.
- 32 2011;8(2):89-99.
- 33 65. Fischer MJ, Scharloo M, Abbink JJ, van 't Hul AJ, van Ranst D, Rudolphus A, et al. Drop-out
- 34 and attendance in pulmonary rehabilitation: The role of clinical and psychosocial variables.
- 35 *Respiratory Medicine*. 2009;103(10):1564-71.
- 36 66. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in
- 37 chronic lung disease: a randomized trial. *Am J Respir Crit Care Med*. 2003;167(6):880-8.
- 38 67. Heppner PS, Morgan C, Kaplan RM, Ries AL. Regular walking and long-term maintenance of
- 39 outcomes after pulmonary rehabilitation. *Journal of Cardiopulmonary Rehabilitation*. 2006;26(1):44-
- 40 53.
- 41 68. Marchetti N, Lammi MR, Travaline JM, Ciccolella D, Civic B, Criner GJ. Air Current Applied to
- 42 the Face Improves Exercise Performance in Patients with COPD. *Lung*. 2015;193(5):725-31.
- 43 69. Farquhar MC, Prevost AT, McCrone P, Brafman-Price B, Bentley A, Higginson IJ, et al. Is a
- 44 specialist breathlessness service more effective and cost-effective for patients with advanced cancer
- 45 and their carers than standard care? Findings of a mixed-method randomised controlled trial. *BMC*
- 46 *Medicine*. 2014;12(1):194.
- 47 70. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in*
- 48 *Medicine*. 2002;21(11):1539-58.
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1  
2  
3 **Airflow relieves chronic breathlessness in people with advanced disease: an exploratory**  
4 **systematic review and meta-analyses.**  
5  
6  
7

8 Flavia Swan, Wolfson Palliative Care Research Centre, Institute for Clinical and Applied Health  
9 Research, Allam Medical Building, Hull York Medical School (HYMS), University of Hull,  
10 Cottingham Rd, Hull, HU6 7RX  
11  
12

13  
14 Alison Newey, Community Palliative Care, University Hospital of South Manchester NHS  
15 Foundation Trust, Withington Community Hospital, Nell Lane, Manchester, M20 2LR  
16  
17

18  
19 Martin Bland, Department of Health Sciences, Seebohm Rowntree Building, University of York,  
20 Heslington, York YO10 5DD  
21  
22

23  
24 Victoria Allgar, Department of Health sciences, University of York, Heslington, York YO10 5DD  
25

26  
27 Sara Booth, Associate Lecturer, Department of Oncology, University of Cambridge, Cambridge CB2  
28 0QQ  
29

30  
31 Claudia Bausewein, Department of Palliative Medicine, Munich University Hospital,  
32 Marchioninstr. 15, 81377 München, Germany  
33  
34

35  
36 Janelle Yorke, School of Health Sciences, Division Nursing, Midwifery and Social Work, University  
37 of Manchester. Room 5.320, Jean McFarlane University, University Place, Oxford Road, Manchester  
38 M13 9PL and Christie Patient Centred Research group (CPCR) The Christie NHS Foundation Trust,  
39 Manchester.  
40  
41  
42

43  
44 Miriam Johnson, Wolfson Palliative Care Research Centre, Institute for Clinical and Applied Health  
45 Research, Allam Medical Building, Hull York Medical School (HYMS), University of Hull,  
46 Cottingham Rd, Hull, HU6 7RX  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

Background: Chronic breathlessness is a neglected symptom of advanced diseases.

Aim: To examine the effect of airflow for chronic breathlessness relief.

Design: Exploratory systematic review and meta-analysis.

Data sources: Medline, CINAHL, AMED and Cochrane databases were searched (1985 – 2018) for observational studies or randomised controlled trials of airflow as intervention or comparator. Selection against pre-defined inclusion criteria, quality-appraisal and data extraction were conducted by two independent reviewers with access to a third for unresolved differences. “Before and after” breathlessness measures from airflow arms were analysed. Meta-analysis was carried out where possible.

Results: 16/78 studies (n=929) were included; 11 randomised controlled trials of oxygen vs medical air, four randomised controlled trials and one fan cohort study. Three meta-analyses were possible: i) Fan at rest in three studies (n=111) offered significant benefit for breathlessness intensity (0-100mm Visual Analogue Scale and 0- 10 Numerical Rating Scale), mean difference -11.17 (95% confidence intervals -16.60 to -5.74), p=0.06 I<sup>2</sup> 64%. ii) Medical air *via* nasal cannulae at rest in two studies (n=89) improved breathlessness intensity (visual analogue scale), mean difference -12.0mm, 95% confidence intervals -7.4 to -16.6, P<0.0001 I<sup>2</sup> =0%. iii) Medical airflow during a constant load exercise test before and after rehabilitation (n=29) in two studies improved breathlessness intensity (mBorg, 0-10) mean difference -2.9, 95% confidence intervals -3.2 to -2.7, p<0.0001 I<sup>2</sup> =0%.

Conclusion: Airflow appears to offer meaningful relief of chronic breathlessness and should be considered as an adjunct treatment in the management of breathlessness.

## Keywords:

- dyspnea,
- self-management,
- review,
- airflow (relevant term as the intervention subject heading)

### What is already known?

- Randomised Controlled Trials (RCTs) and cohort data have demonstrated that airflow delivered from the fan at rest offers significant relief of breathlessness.
- Systematic review (SR) and RCTs of oxygen vs medical air have failed to demonstrate additional benefit from oxygen therapy and suggest that medical air delivery, airflow, is likely to be an active intervention.
- All current evidence available for the effect of airflow for chronic breathlessness relief has not been explored using SR methods.

### What this paper adds

This exploratory SR and meta-analyses provide promising data to suggest that:

- airflow from the fan at rest improves breathlessness in people with breathlessness due to a variety of causes
- airflow delivered as cylinder medical air at rest improves breathlessness in advanced cancer
- airflow delivered as cylinder medical air during a constant load exercise test in people with chronic obstructive pulmonary disease and who have completed pulmonary rehabilitation

### Implications for practice and theory

- Clinicians should consider the fan as an adjunct to treatment for breathlessness at rest in patients who do not require oxygen-enriched air.
- Airflow may benefit exertion-induced breathlessness, but further work is required to investigate the role of the fan with everyday general activity and in relation to exercise.
- Recovery time from exertion-induced breathlessness, self-efficacy and daily activity are key outcomes to explore in future studies of airflow.

## Introduction

Breathlessness is a common, often poorly managed symptom in people with advanced diseases. It is associated with reduced quality of life (1), decreased activities of daily living (2), unplanned emergency hospital attendance and admission. (3-5) Breathlessness inflicts devastating and disabling physical, psychological and social burden on normal daily life for the patient, carers and close family members (6-8). Chronic breathlessness, that is, breathlessness that persists despite optimal treatment for the underlying pathophysiology and causing such disability (9), all too often is left for patients to manage themselves despite a developing evidence base for interventions targeted at the breathlessness itself.

Growing evidence supports complex non-pharmacological interventions to reduce the impact of the symptom and improve quality of life. (10-12) Components target peripheral and central afferent sources of breathlessness sensation, such as facial airflow delivered by the battery-operated hand-held fan (fan). (13-17) Cooling of the facial skin innervated by the 2<sup>nd</sup> and 3<sup>rd</sup> branches of the trigeminal nerve, nasal mucosae or the upper airway flow receptors could modulate the central perception of breathlessness leading to decreased neural respiratory drive, thereby reducing the sensation of breathlessness. (18-22) A recent multi-methods secondary analysis of qualitative interview data from three studies found that 80/111 (72%) participants experienced benefit when the fan was used in conjunction with other components of a complex intervention. (23) Airflow delivered from the fan may offer a valuable contribution to the self-management of chronic breathlessness (13, 15, 23), and has been identified as a potentially useful strategy in a variety of situations, e.g. breathlessness crisis (24), a component of pulmonary rehabilitation to assist recovery from exercise, or with general everyday activities. (15)

Systematic reviews (SR) of oxygen in a variety of non-hypoxic patient groups (cancer, chronic heart failure, kyphoscoliosis, COPD and ILD) have not demonstrated additional benefit from oxygen therapy over medical air delivery. (25-30) An updated Cochrane review of COPD found low quality evidence for modest relief of breathlessness. (31) The results from a large, adequately powered trial that randomised 239 participants (COPD 63%, cancer 16%) to receive at least 15 hours a day of oxygen or medical air delivered via home concentrator for seven days reaffirms earlier suggestion that medical air used in the placebo arm may not be an inert comparator as previously thought and points to the likelihood of an

1  
2  
3 active intervention. (29, 32) Therefore the placebo arm of oxygen studies may provide useful  
4 preliminary data regarding the role of airflow for the relief of chronic breathlessness. This  
5 systematic review aims to identify and evaluate data from studies of airflow, both from  
6 studies of the hand-held fan and the comparator arm data for breathlessness intensity from  
7 oxygen studies, analysed as “before and after” airflow exposure cohort data.  
8  
9  
10  
11  
12

### 13 **Aim**

14  
15  
16 To examine the current evidence for the effectiveness of airflow for the relief of chronic  
17 breathlessness.  
18  
19

### 20 **Methods**

21  
22  
23 The SR methods employed an exploratory approach in that only the airflow arm of studies  
24 were used and the data analysed as cohort “before and after” treatment.  
25  
26  
27  
28

### 29 **Study design**

30  
31  
32 The search methods employed are adapted from the Cochrane Handbook of Systematic  
33 Reviews (33) and reported in accordance with the Preferred Reporting Items for Systematic  
34 Reviews and Meta-Analyses (PRISMA). (34) A review protocol is not pre-registered but  
35 available from the University of Hull Library (Flavia Swan PhD Thesis).  
36  
37  
38  
39  
40

### 41 **Inclusion and exclusion criteria**

#### 42 **Types of studies**

43  
44  
45 Randomised Controlled Trials (RCTs), controlled clinical trials (quasi-randomised  
46 experimental trials with or without blinding) and observational cohort studies were included.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Types of participants

Adults with chronic breathlessness from any advanced disease aetiology as shown below:

- Malignancy: advanced primary and metastatic cancer patients, who have undergone disease treatments like chemotherapy, radiotherapy or surgical interventions.
- Chronic Obstructive Pulmonary Disease (COPD) with forced expiratory volume in 1 second (FEV<sub>1</sub>) of less than 50% predicted value
- Interstitial lung disease or pulmonary fibrosis where breathlessness is present
- Chronic heart failure: New York Heart Association (NYHA) stage III-IV
- Motor Neurone disease and other neurological disease where breathlessness is present or forced vital capacity (FVC) less than 80% predicted value
- Kyphoscoliosis: a moderate - severe sideways and forwards curvature of the spine Cobb Angle > 50° and FEV<sub>1</sub> of less than 50% predicted value.

Studies were included if at least 50% of the study population were classified as advanced, palliative or in the later stages of disease as defined above. These criteria were adapted from the Cochrane review of non-pharmacological interventions for breathlessness. (35)

Studies of participants with mild hypo or normoxaemia, who do not fore-fill the criteria for Long term Oxygen Therapy (LTOT) (36) were included. Studies of hypoxic participants or patients with any condition not assessed as progressive, refractory to treatment and advanced such as asthma were excluded.

## Types of exposure

Airflow: i) delivered from either a fan (hand-held or table) or non-oxygen enriched compressed air, or from a non-invasive ventilatory method (nasal cannula, mask or mouthpiece), but not Nasal Intermittent Positive Pressure Ventilation (NIPPV) and ii) directed at the cheek of the face, nasal mucosae or mouth.

Administration: as i) a single dose *during ambulation*, or *at rest* taken as needed (PRN *pro re nata*),(37) ii) placebo short-burst oxygen therapy (SBOT) intermittent use *before exercise* or

1  
2  
3 *after* exercise for recovery (36) or iii) continuously over 15hr a day as placebo long-term  
4 oxygen therapy (LTOT) studies or during the night as placebo nocturnal oxygen therapy  
5 (NOT studies) .(38)  
6  
7  
8  
9

10 Studies where airflow was directly administered to the trachea, or at sub-zero temperatures  
11 were excluded.  
12  
13

## 14 **Types of outcome measure**

### 15 **Unidimensional breathlessness outcomes**

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

ATS domains of dyspnea measurement (20) including breathlessness severity or intensity rated on uni-dimensional scales as shown below:

- Modified Borg Score, a categorical scale with ratio properties
- Visual Analogue Scale (VAS), 0 - 100mm anchored 0 = no shortness of breath and 100mm = shortness of breath as bad as can be
- Numerical Rating Scales (NRS), 0-10 numbered scale anchored 0 = Not breathless at all and 10 the worst imaginable breathlessness
- Likert scales with verbal responses such as “a bit better”, “much better” or “no difference” or any other validated uni-dimensional scale for measuring breathlessness.

Studies were only included if they reported the breathlessness outcome at baseline and post-treatment measured as either primary or secondary outcomes. If severity or intensity was measured as part of a multi-dimensional or composite scale, e.g. the Chronic Respiratory Questionnaire, that unidimensional measure of breathlessness was *not* extracted and analysed separately. Breathlessness related function/quality of life measures were *not* used as primary breathlessness outcomes in the absence of unidimensional scales.



## Other Outcomes

Other outcomes as shown below measured as either primary or secondary outcomes.

- Participant preference and satisfaction with the treatment
- Participant withdrawal and drop-out from the studies
- Adverse effects recorded

## Data sources and searches

Medline, CINAHL, AMED and Cochrane databases were searched (1985 – 2015; updated January 2018) for observational or randomised controlled trials (RCTs) of airflow as intervention *vs* control or as comparator *vs* oxygen. Reference lists were scanned. A full search strategy can be seen in Online Supplementary Table 1.

## Study selection

Titles, abstracts (and, where unclear, full papers) were screened against the eligibility criteria by two independent reviewers FS and AN, with recourse to MJ as a third reviewer in case of disagreement.

## Data extraction and synthesis

Baseline and post-intervention measures of breathlessness intensity were extracted from the fan studies and from the comparator arm of oxygen studies. Data were analysed as “before and after” airflow exposure cohort observational data.

## Risk of bias

FS and AN judged the reporting quality and internal validity for each of the included studies. The cohort study was evaluated according to the Cochrane guidelines for assessing bias in a non-randomised study. (39) As there is no tool that is applicable directly to the data extracted from the RCTs control arms, we assessed instead the quality of the parent RCTs as a proxy

1  
2  
3 marker for quality data. The RCTs were assessed with the Cochrane Risk of bias tool. (33)  
4 See online Supplementary Table 2.  
5  
6  
7

## 8 **Statistical Analysis**

9

10  
11 Results from the meta-analyses were reported for the primary outcome, breathlessness  
12 intensity or severity where heterogeneity allowed, or where not possible these were described  
13 narratively. NRS and VAS scales were combined by equating one point on a NRS scale to  
14 10mm on a VAS. (40, 41)  
15  
16  
17  
18


19  
20 Data calculations for mean difference and SD used STATA Version 12.1, Stata Corp LLC  
21 Texas 77845-4512, USA. Breathlessness measurements were analysed as continuous  
22 outcomes. Data from the placebo arm of cross-over RCTs were treated as single arm before-  
23 after studies. For studies that recorded median values, the mean were calculated from the  
24 extracted study data. (42) The  $I^2$  statistic was used to assess heterogeneity. (43) Where the  
25 result indicated significant heterogeneity a random effects model was chosen, otherwise a  
26 fixed effects model was applied. All analyses were undertaken on Review Manager 5.5. A  
27 sensitivity analysis was attempted for any study identified as including a sub-group not fitting  
28 the review criteria of mild hypo or normoxaemia to assess for any significant difference in  
29 the breathlessness outcome between the hypoxic and non-hypoxic participants.  
30  
31  
32  
33  
34  
35  
36  
37

## 38 **Results**

39

40  
41 A total of 403 records were identified for screening. After removal of duplicates, 78 records  
42 were reviewed. 14 abstracts were rejected for not meeting inclusion criteria; the remaining 64  
43 full text articles were assessed for eligibility. Of these, 16 studies met the review inclusion  
44 criteria and the other 48 studies were excluded (see Figure 1; PRISMA flow chart (34) and  
45 Online Supplementary Table 3, eAppendix).  
46  
47  
48  
49

50  
51 Overall studies represented 929 participants (age median 61.5, range 33 to 90 years; 47%  
52 men)  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1** PRISMA 2009 Flow-diagram of study selection and retrieval (34)

Airflow was delivered by fan (13, 14, 16, 17, 44) or as medical air. (29, 32, 45-53) See Table 1 for study characteristics

## Description of fan studies

**Design:** five studies (n=230) used the fan. Two feasibility RCTs; (n =49), (13) and (n=30), (44), a feasibility cohort study (n=31), (14), a feasibility longitudinal RCT (n=70), (16) and a phase III cross-over RCT (n=50), (17).

**Patient characteristics:** Four studies recruited a mixed population of people with breathlessness due to a variety of advanced conditions including COPD (n=101), cancer (n=55), heart failure (n=23) and other causes (n=21), (13, 14, 16, 17), and one study recruited advanced cancer only (n=30). (44)

**Intervention and comparator characteristics:** three studies used the fan to face at rest (14, 17, 44), two with comparator groups; fan to leg (17), or no fan use and carer support (44), and the other was a cohort design. (14) One study assessed acceptability of the fan when used with general activity over 6 months compared with an acupuncture wristband (16), and the remaining study assessed the fan when used with exercise advice over 4 weeks. (13)

**Breathlessness Outcome:** Three studies focused on the sensory-perceptual domain of dyspnea measurement and used breathlessness intensity as the primary outcome (17) or main outcome (14, 44). These studies selected the VAS (17), the NRS (44), or both VAS and NRS (14). The other two studies assessed symptom impact as well as the sensory-perceptual domain. These studies selected the NRS breathlessness intensity (13) and the Modified Borg Scale of breathlessness severity. (16)

**Other outcomes:** All of the fan studies reported participant withdrawals (13, 14, 16, 17, 44). These ranged from 0 to 6 participants. (13, 14, 44) One study reported that there were no Adverse Events (AE) (13) and the other fan studies did not include any AE details. (14, 16, 17, 44) Airflow preferences were described in four fan studies (13, 16, 17, 44) and not in one study. (14) In addition, one study quantified the experience of fan use at 2 months. (16)

## Description of medical air studies

**Design:** eleven RCT's (n=699) used oxygen, helium hyperoxia or both gases for the intervention compared with medical air. (29, 32, 45-53) Study size ranged from 16 to 239

1  
2  
3 participants. (29, 48) Four were cross-over (32, 48, 49, 51) and seven used a parallel group  
4 design. (29, 45-47, 50, 52, 53) Nine studies were double blind (29, 45-52), and two were  
5 single blind. (32, 53)  
6  
7  
8  
9

10 **Patient characteristics:** the eleven studies represent; COPD n=537, cancer n=109, other lung  
11 diseases n=21, cardiac disease n=14 and other causes n=18. Inclusion criteria required  
12 moderate to severe COPD (45-50, 52, 53), advanced cancer (51), or were a mixed population  
13 with no specific stipulation of severity. (29, 32)  
14  
15  
16  
17

18 **Intervention Characteristics:** the source of airflow was an oxygen cylinder (32, 45-50), a  
19 sham concentrator (29), and a Douglas bag. (52) Two studies did not state the airflow source.  
20 (51, 53) Medical air or compressed air was delivered through nasal cannulae (29, 32, 45, 47,  
21 49-51, 53), face-mask and nasal cannula (48), a non-rebreathing face-mask (46) and through  
22 a mouthpiece. (52) The flow rates varied widely in the studies; 2l/minute (29, 45), 3l/minute  
23 (47), 4l/minute (32, 49, 51), 5l/minute (53), 6l/minute (50) and 8l/minute *via* nasal cannula or  
24 15l/minute with face mask. (48) Two studies did not report flow rate details. (46, 52) The  
25 timing of airflow delivery was; 15 minutes at rest (32, 51), with daily activity over 3 (50), or  
26 6 months (45), 15 hours a day over one week (29), or in conjunction with exertion-induced  
27 breathlessness during pulmonary rehabilitation (PR), (46, 52, 53) or a walking test. (47-49)  
28 The PR programme parameters for airflow delivery were with treadmill exercise 3 times a  
29 week for 30 minutes over two months (53), a cycle ergometer used 3 times a week for 30  
30 minutes over 6 weeks (46), or 3 times a week for 20 minutes over two months. (52) The  
31 6MWT test parameters for airflow delivery were; i) three same day 6MWTs with 45 minutes  
32 washout, using room air for the basal walk and compressed air for the subsequent walks (47),  
33 ii) five 6MWTs performed over three visits, (timing not stated) using room air for the practice  
34 walk on visit one and cylinder air for the two 6MWTs with 60 minute washout on visits two  
35 and three (48), and iii) three same day 6MWTs using cylinder air with 20 minutes washout  
36 between tests at baseline, 6 and 12 weeks as well as short burst use at home with daily  
37 activity during the study period. (49)  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 **Breathlessness outcome:** two studies focused on the sensory-perceptual domain of dyspnea  
55 measurement and recorded breathlessness intensity as a primary outcome with the VAS and  
56 Borg scale (32) or the VAS only. (51) All of the other studies focused on symptom impact as  
57 well as the sensory-perceptual domain. (29, 45-50, 52, 53) Of these, three studies measured  
58  
59  
60

1  
2  
3 breathlessness intensity as a primary outcome with the NRS (29) or the CRQ dyspnea  
4 domain. (45, 50) The remaining six studies identified the modified Borg scale as one of the  
5 main outcomes (47-49, 52, 53) or a secondary measure. (46) One study in addition selected  
6 the CRQ. (49)  
7  
8  
9

10  
11 **Other outcomes:** participant withdrawals were reported in all of the studies (29, 32, 45-51,  
12 53), apart from one. (52) Five studies reported no withdrawals (32, 46-48, 51) and in the  
13 other five studies withdrawals ranged from 2 to 21 participants. (45, 53) AE were poorly  
14 reported with only two studies including details; “few” or “no AE”. (29, 46) All of the other  
15 studies omitted reporting AE. (32, 45, 47-53) Airflow preferences were only reported in one  
16 study. (51) The remaining studies did not report airflow preferences (29, 32, 45-48, 50, 52,  
17 53), although one study did quantify side-effects (29) and a second study examined  
18 preference for cylinder delivery of airflow. (50)  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 Characteristics of included studies (fan)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, Adverse Events (AE), airflow preferences	Timing of measurement	Results airflow arm only (before and after treatment)	Improvement with airflow Yes/No
Booth (2016) [14]	Feasibility observational cohort	n= 31 Males: 20 Age mean: 74.8 SD 11.49  Mixed population, non-malignant, cardiorespiratory disease: 8 (26%)  Baseline dyspnoea score:  Mean VAS 48mm SD 27.4	Hand-held fan to face	No comparator group	Airflow from hand-held fan to face for 5 minutes	VAS (mm), NRS	Withdrawals = 6  AE and airflow preferences not reported	After 5 minutes at rest	VAS = Mean 35mm SD 25.7  after 5min air  Mean change = 12mm SD 21.2	Yes
Bausewein (2010) [16]	Feasibility longitudinal phase II RCT	n = 70 Males: 36 Age mean: 65.6yrs SD 8.80 COPD = 45, cancer = 25  Baseline dyspnoea score: 3.7 (1.83)	Hand-held fan to face	Wristband	Airflow from hand-held fan	Modified Borg score	Withdrawals at 2 months =16/33 (48%)  AE not reported  Airflow preferences: Positive = 13/38 Negative = 7/38	Monthly over 6 months	Mean Borg score change over 2 months = 0.6 (SD 2.1 ), p = 0.90	No, phase II not powered to test
Galbraith (2010) [17]	Cross-over RCT	n = 50 Males: 23 Age mean: 71.3, range 33-90yrs  Mixed population; COPD = 26, lung cancer = 11, heart disease = 15  Baseline dyspnoea score:  VAS Fan/face 1st group = 31mm (SD 12-61mm)	Hand-held fan to face	Hand-held fan to leg	Airflow from hand-held fan to face for 5 minutes	VAS (mm)	Withdrawals = 1  AE not reported  Airflow preferences: positive patient comments, numbers not reported	After 5 minutes at rest and after 10 minute washout	VAS = -7.0mm Median change after 5 minutes Fan/face 1st group (IRQ 1.5 - 14.5)  VAS = -10.0mm Median change incl 10 minute washout Fan/face 1st group (IRQ 3.5 – 17), P=0.003	Yes

**Table 1 Characteristics of included studies (fan)**

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results: airflow arm only (before and after treatment)	Improvement with airflow Yes/No
Johnson (2016) [13]	Feasibility phase II RCT	n =49 Males: 26 Age mean: 68 (range 46-88) Mixed population; COPD = 28, cancer =9, heart disease = 5, others = 7 Baseline dyspnoea score Mean NRS = 5.7 (SD 1.5)	Hand-held fan to face at high or low flow rate	Usual care: verbal and written exercise and breathlessness management advice	Airflow from hand-held fan	NRS	Withdrawals = 6 No AE Airflow preference: positive patient comments, numbers not reported	After 4 weeks	NRS = 6.0 (2.0) at 4 weeks Mean change 0.0 (3.0)	No, phase II not powered to test
Wong (2017) [44]	Feasibility phase II RCT	n=30 Males: 14 Age: NR Lung cancer = 13, other cancers = 17 Baseline dyspnoea score Control group: NRS mean 5.6 (SD 1.55) Intervention group: NRS mean 6.13 (SD 2.48)	Table fan with low flow rate	Placebo accompanied by carer	Airflow from table fan to face for 5 minutes	NRS	No withdrawals AE not reported Airflow preference: mixed patient comments, numbers not reported	After 5 minutes at rest	NRS = 4.60 after 5 minutes fan to face Mean change -1.53 (1.06) p< 0.001	Yes



Table 1 Characteristics of included studies (medical air)

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results airflow arm only (before and after treatment)	Improvement with airflow Yes/No
Abernethy (2010) [29]	Double-blind RCT	n = 239 Males: 63% Age mean: Air = 74yrs (SD 10) Mixed: COPD = 152, Primary lung cancer = 33 Baseline dyspnoea score: Am air = 4.6 (SD 2.4) Pm air = 4.7 (SD 2.3)	Oxygen	Room air via concentrator	2l/min via nasal cannula for at least 15hrs a day (LTOT)	NRS 1-10	Withdrawals = 15 Few AE, number not reported Side-effects reported Airflow preferences not reported, oxygen only	Am and pm each day, within 30 minutes of waking and bedtime for 7 days	Am = -0.7 NRS point change Pm = -0.5 NRS point change, (p = 0.5)	Yes
Booth (1996) [32]	Single-blind cross-over RCT	n = 38 Males: 22 Age Median: 71 Range: 54-90yrs Lung Cancer 20, COPD 13, Cardiac 4 Baseline dyspnoea score: VAS 59mm	Oxygen	Cylinder air	4l/minute for 15 minutes via nasal cannula	VAS (mm) Modified Borg Scale	No withdrawals AE and airflow preferences not reported	After 15 minutes of breathing oxygen or air at rest.	VAS = -11mm change after air 48mm, p<0.001	Yes
Eaton (2006) [45]	Double-blind parallel RCT	n = 78 Males: 36 Age mean: 77.3yrs (7.06) Moderate/severe COPD Baseline CRQ score: Air = 17.5 (SD 4.2)	Oxygen	Cylinder air	2l/minute via nasal cannula over 6 months (SBOT)	CRQ	Withdrawals = 21 AE and airflow preferences not reported	Monthly over 6 months	CRQ = Average change over 6 months: air group = -3.6	No

**Table 1 Characteristics of included studies (medical air)**

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results airflow comparator arm only (before and after treatment)	Improvement with airflow Yes/No
Eves (2009) [46]	Double-blind RCT	n = 38 Males: 23 Age mean: 65.5yrs (SD 8) Stable COPD Baseline dyspnoea score: constant load exercise Borg mean: Air = 6.0 (SD 2.2) incremental load exercise Borg mean: Air = 5.6 (SD2.0)	Helium-hyperoxia (60% HE: 40% O <sup>2</sup> )	Cylinder air	Face mask (non-rebreathing)	Modified Borg score	No withdrawals No AE Airflow preferences not reported	During exercise test before and after 6 weeks pulmonary rehabilitation programme, 3 times a week for 30 minutes on cycle ergometer	constant load exercise Borg mean: Air = 4.2 (SD 2.1) mean change = -1.8 (95% CI -3.1 to -0.2), p < 0.05 incremental load exercise Borg mean: Air = 5.6 (SD 2.1) No change (95% CI -0.7 to 0.7)	Yes
Jolly (2001) [47]	Double-blind RCT	n = 20 Males: 19 Age mean: 68.5yrs (SEM 2.5) Stable COPD Baseline dyspnoea score: Borg mean score Desat group Baseline 6MWT = 5.82 (SEM 0.46) Non-desat group Baseline 6MWT = 4.22 (SEM 0.46)	Oxygen	Cylinder air	3l/minute via nasal cannula	Modified Borg score	No withdrawals AE and airflow preferences not reported	Before and after 3 x 6 MWTs with at least 45minutes washout between walks	Borg mean score: Desat group Air 6MWT = 5.82 (SEM 0.42) No change Non-desat group Air 6MWT = 4.44 (SEM 0.73) No change	No
Marciniuk (2007) [48]	Double-blind crossover RCT	n = 16 Males: 7 Age mean: 67 (SD 8) Moderate to severe COPD Baseline dyspnoea score: Borg mean score Baseline 6MWT = 5 (SD 2)	100% Oxygen or Helium-hyperoxia (70% HE: 30% O <sup>2</sup> )	Cylinder air	15l/minute via face mask 8l/minute via nasal cannula	Modified Borg score	No withdrawals AE and airflow preferences not reported	Before and after each 6 MWTs on visit 1,2 and 3 with 60 minutes washout between walks	Borg mean score After 6MWT Air = 3.5 mean Borg score change = -1.5 decrease	Yes

Table 1 Characteristics of included studies (medical air)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results airflow comparator arm only (before and after treatment)	Improvement with airflow Yes/No
McDonald (1995) [49]	Double-blind crossover RCT	n = 26 Males: 24 Age mean: 73 (SD 6) Stable severe COPD Baseline dyspnoea score 6MWT: Air group = 3.8 (SD 1.4) CRQ = 14 (SD 5)	Oxygen	Cylinder air	4l/minute via nasal cannula	Modified Borg score CRQ	Withdrawals = 7 AE and airflow preferences not reported	After 6 and 12 weeks of home cylinder air using 6MWT exercise test with 20 minute washout between walks	Borg Mean score Home air: 6MWT with cylinder air = 3.8 (SD 1.5) No change CRQ score Home air = 17 (SD 6) 3 point change	No with 6MWT Yes with CRQ
Moore (2011) [50]	Double-blind RCT	n = 143 Males: 99 Age mean: 71.8yrs (SD 9.8) Range: 43-78 Stable COPD Baseline dyspnoea score: Air = 17.5 (SD 4.9)	Oxygen	Cylinder air	6l/minute via nasal cannula at home for 12 weeks with activity (SBOT)	CRQ	Withdrawals = 4 AE not reported Airflow preferences 45% prefer no cylinder	At 4 weeks and 12 weeks	Air: 4 weeks = 18.4 (SD 5.8) 12 weeks = 18.4 (SD 5.8) Air: CRQ = Mean change at 4 and 12 weeks = 0.9	Yes
Philip (2006) [51]	Double-blind cross-over RCT	n = 51 Males: 31 Age median: 65 Range: 33-82yrs NSCLC = 22, Small cell lung cancer = 6, Breast = 8, Colorectal = 4 Others = 11 Baseline dyspnoea score: VAS median Air 1st = 52mm (range 23-92) VAS median Air 2nd = 42mm (range 10-70)	Oxygen	Medical Air	4l/minute for 15 minutes via nasal cannula	VAS (mm)	No withdrawals AE not reported Airflow preferences: Positive: n=15 (29%)	Before and after 15 minutes of gas	VAS median After air 1st = -3mm change (range -19 to 7) VAS median After air 2nd = -11.5mm change (range -20 to 45) VAS mean change = -13.4mm	Yes

**Table 1 Characteristics of included studies (medical air)**

Study author	Study Design	Population	Intervention	Comparator	Mode of gas delivery	Dyspnea Outcome measure(s)	Other Outcomes: withdrawals, AE, airflow preferences	Timing of measurement	Results airflow comparator arm only (before and after treatment)	Improvement with airflow Yes/No
Scorsone (2010) [52]	Double-blind RCT	n = 30 Males: 23 Age mean: 67.3yrs (SD 8.3) Moderate to severe COPD Baseline dyspnoea score: Before training incremental load exercise Borg: Air = 7 (SD 3) Before training constant load exercise Borg: Air = 8 (SD 3)	40% Oxygen or Helium - hyperoxia (60% HE: 40% O <sup>2</sup> )	Humidified room air	Mouthpiece from a Douglas bag	Modified Borg score	No withdrawals AE and airflow preferences not reported	During exercise before and after a 2 months pulmonary rehabilitation programme, 3 times a week for 20 minutes on cycle ergometer	After training incremental load exercise Borg: Air = 4 (SD 2) After training constant load exercise Borg = 5 (SD 3) Borg change = -3 point decrease both exercise tests	Yes
Wadell (2001) [53]	Single-blind crossover RCT	n = 20 Males: 10 Age mean: 67yrs Range: 52-73 Stable COPD Baseline dyspnoea median score: Test A (Air) At rest; Pre-training Borg: Air group = 1.5 (0-3) Test A (Air) After 6MWT, Pre-training Borg: Air group = 6.5 (4-9)	Oxygen	Air	5l/minute via nasal cannula	Modified Borg score	Withdrawals =2 AE and patient preferences not reported	During exercise using 2 x 6MWT (air/O <sup>2</sup> or O <sup>2</sup> /air) with 1hour washout before and after a 2 months pulmonary rehabilitation programme, 3 times a week for 30 minutes on a treadmill	Test A (Air) At rest; Post-training Borg: Air group = 1 (0-3) Test A (Air) After 6MWT, Post-training Borg: Air group = 6 (1-7) Borg change = -0.5 point at rest and after exercise test	Yes

## Risk of Bias

The quality appraisal is summarised in Online Supplementary Table 2 and described below.

**Allocation:** all of the studies, apart from one, a cohort design (14), were described as RCTs. It was possible to verify the randomisation process in eight studies. (13, 16, 17, 29, 32, 45, 46, 50). There was insufficient information to determine the risk of allocation bias in the other RCTs. (44, 47-49, 51-53)

**Blinding:** two of the fan studies attempted to blind the participants (16, 17); a placebo wristband was used as a comparator (16) and participants were not told if the fan to face or fan to leg was the active intervention. (17) There was no blinding in two studies, a cohort and phase II RCT (13, 14), and the fifth study stated single blinding that could not be verified from the methods described. (44) All five were judged high risk of bias due to incomplete blinding or limited description. Nine medical air RCTs were described as double blind. (29, 45-52) All were judged low risk of bias (29, 45, 46, 48-50, 52), apart from one study that was unclear due to the lack of detail reported. (51) Two RCTs were single blind (32, 53); one was judged low risk of bias (32) and the other was regarded as unclear risk due to the inadequate description. (53)

**Incomplete outcome data:** 13 studies adequately addressed withdrawals and incomplete outcome data; these were considered low risk of bias. (13, 14, 17, 29, 32, 46-53) Three studies were uncertain risk (16, 45); one due to the proportion of attrition (16) and the other two lacked description of how any missing data were statistically managed. (44, 45)

**Selective Outcome reporting:** all of the studies reported the pre-specified outcomes and were judged as low risk of bias. (13, 14, 16, 17, 29, 32, 44-53) Study protocols were available for eight studies. (13, 14, 16, 17, 29, 46, 50, 51)

**Other issues of bias:** twelve studies appeared free from other bias and were judged low risk. (13, 16, 17, 29, 44-46, 48, 50-53) Three studies reported insufficient information to adequately assess risk (32, 47, 49), and one study, a cohort design was judged high risk. (14)

## Effect of interventions

The airflow was delivered, i) at rest (14, 17, 32, 44, 51) ii) over days or weeks (either intermittently or as periods of continuous flow) whilst the participant continued with usual general activities (13, 16, 29, 45, 50) or iii) during specific episodes of exertion induced breathlessness. (46-49, 52, 53)

### i) At rest

Five studies demonstrated improvement with airflow delivery at rest.

Results from 5 minutes fan use to the face in three studies were VAS breathlessness intensity difference from baseline mean -7mm (CI -11.5 to -2.5) (17), and mean -12mm (CI -19.3 to -4.4) (14), and for the NRS mean change -1.53 (-9.6 to -6.5).(44)

Cylinder medical air delivery for 15 minutes demonstrated improvement VAS breathlessness intensity mean -11mm (CI -17.0 to -5.0) (32), and mean -13mm (CI -20.5 to -6.3). (51) Four studies were sub-divided into two groups and included in meta-analyses.

### *Fan*

Airflow from the fan at rest improved breathlessness in a mixed population (n=111; 58% cancer) VAS (mm) mean difference (MD), -11.17 (CI -16.60 to -5.74), p=0.06. Significant heterogeneity was observed, Chi<sup>2</sup> p-value = 0.2, (I<sup>2</sup> = 64%) (See Figure 2).

<<insert Figure 2 Meta-analysis of fan at rest >>

### *Medical air*

Airflow delivered as cylinder medical air at rest improved breathlessness in advanced cancer (n=89) VAS (mm) MD -12.0, (CI -16.6 to -7.4), P<0.0001. No evidence of heterogeneity was observed, Chi<sup>2</sup> P value = 0.6, (I<sup>2</sup> =0%).

<<insert Figure 3 Meta-analysis of cylinder air at rest >>

## ii) General activity

Six studies used airflow at home with everyday general activity. A narrative description was used for these due to study diversity. Breathlessness points change from four cylinder air studies were mixed (29, 45, 49, 50), with CRQ -3.6 after 6 months (45), 3.0 after 12 weeks (49), or 0.9 at 12 weeks (50), or NRS -0.7 (am) and -0.5 NRS (pm) after 7 days. (29) In the two fan studies a modified Borg score of -0.6 (SD 2.1) was found after 2 months (16), but there was no NRS score change after 4 weeks of fan use with exercise advice. (13)

## iii) Exertion-induced breathlessness

Six studies examined airflow delivery with exertion-induced breathlessness. Results for mean Borg breathlessness score during a walking test for three studies varied; no change during a 6MWT repeated on the same day (47), or at 12 weeks (49), and improvement -1.5 for a 6MWT repeated on 3 separate visits. (48) Airflow delivered during a constant load exercise test after PR in three studies also demonstrated variable improvement in mean Borg breathlessness scores; -1.8 points (46), and -3 point (52) using a cycle ergometer, and -0.5 point from a treadmill test. (53) Two studies were suitable to include in a meta-analysis (See Figure 4). (46, 52)

### *Medical air*

Airflow delivered as cylinder medical air during a constant load exercise test after PR in COPD (n=29) significantly improved breathlessness Borg score MD -2.9, (CI -3.2 to -2.7),  $p < 0.0001$ . No evidence of heterogeneity was observed,  $\text{Chi}^2$  p-value = 0.7, ( $I^2 = 0\%$ ), (Figure 4).

<< insert Figure 4 Meta-analysis of cylinder medical air for exertion-induced breathlessness >>

## Discussion

These exploratory data support that facial and nasal airflow delivery at rest offers relief of breathlessness intensity consistent with a moderate clinically important difference, (54, 55) and during exertion. (46, 52) **All participants in the cylinder medical air delivery at rest studies had advanced cancer, but nearly half of those in the fan “at rest” studies had other conditions indicating that airflow for breathlessness at rest is of benefit irrespective of cause.**

In a recent pooled qualitative data study of facial airflow use from the fan in 133 people with chronic breathlessness (56), over 80% patients reported some or substantial benefit.(57) However, the data presented here varied with regard to relief of breathlessness intensity when facial or nasal airflow delivery was used with everyday general activity or with exertion induced breathlessness. This may reflect the use of outcome measures that do not reliably capture change in breathlessness intensity in the context of exertion. Studies that used a 6MWT (47-49) highlight the problem of a self-paced test that allows patients to control their walking speed and thus limit the maximal level of exertion–induced breathlessness experienced. In contrast, studies that used an externally paced test, such as the cycle ergometer, identified relief of breathlessness intensity. (46, 52) The relationship between exercise and breathlessness intensity is complex, and measuring one without taking the other into account may miss relevant improvement. Scores are likely to remain static after the introduction of an intervention as patients are able to exert themselves to the same level of breathlessness without noticing an increase in their exercise tolerance (58), or indeed the outcome may be of little value to the patient. (57)

A previous study of recovery time after an ISWT in people with thoracic cancer (n=57) reported a rapid reduction in breathlessness intensity with a return to baseline time of median 4 (IQR 2-5) minutes. (59) The analysis of 133 patient interviews found that a faster recovery time was a key patient-reported benefit of airflow delivered from the fan, irrespective of breathlessness intensity. (57) Even though recovery time may only be a matter of minutes, interventions which shorten this further are clearly welcomed and give the patient a sense of self-control that may help prevent a breathlessness-anxiety spiral. The ability to recover quickly and predictably from bouts of exertion is likely to encourage further activity and prevent the deconditioning cycle.



1  
2  
3 The fan therefore seems suitable as a patient-delivered intervention to target the recovery  
4 time from exertion-induced breathlessness. Preliminary magnetoencephalography (MEG)  
5 imaging data suggests airflow delivery during recovery from exercise may modulate central  
6 perception of breathlessness by modifying sensory attention. (60) Cooling of the facial skin  
7 innervated by the 2<sup>nd</sup> and 3<sup>rd</sup> branches of the trigeminal nerve and/or stimulation of nasal  
8 mucosa and upper airway ‘flow’ receptors are reported to improve breathlessness intensity  
9 and exercise tolerance (18, 19, 61, 62) and could “fool” the brain into thinking that the  
10 respiratory status is adequate. (22)  
11  
12

13  
14  
15  
16  
17  
18 Unpleasant respiratory sensations associated with exercise are known to adversely influence  
19 adherence to an exercise regime. (63) Therefore, use of airflow as part of PR may help the  
20 problems of low patient attendance and poor maintenance of long term outcomes. (64-67)  
21 Facial airflow from fan use during a cycle ergometer test in COPD patients resulted in  
22 significant breathlessness reduction and a longer total exercise time. (68) Likewise, the meta-  
23 analysis result from this SR suggest significant relief of breathlessness when airflow is  
24 delivered during exercise. These data highlight the potential value of using airflow delivery  
25 with PR or home based exercise programmes. In addition, intervention preference and AE  
26 data support the role of the fan in this context as a portable device that is unlikely to harm and  
27 therefore appropriate for the majority of patients to try.  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 Finally, it is likely that any positive benefits of airflow delivery from fan use with everyday  
38 general activity and at rest were not captured in the review data. The lack of signal from the  
39 results may in part reflect the complexity and the nuances of when, where and how this  
40 intervention is used by patients. (57) Current breathlessness management is modelled on a  
41 complex intervention, of which the fan is identified as a valuable therapeutic component  
42 alongside other interventions and strategies that are tailored to the patient’s breathlessness  
43 needs. (11, 69)  
44  
45  
46  
47  
48  
49  
50

### 51 **Limitation of methods**

52  
53

54 Data were analysed as cohort “before and after” design, and no adjustments were made to  
55 control for confounding bias. The pre-post comparison increases the potential risk of bias and  
56 it is possible that results may be influenced by the timing of “before and after” measures. For  
57 example, studies of longer duration (up to 6 months) may not be representative of the  
58  
59  
60

1  
2  
3 immediate benefits of airflow, but rather reflect more complex use and mechanism of any  
4 observed benefit may be related to reconditioning, facilitated by airflow, over time. Risk of  
5 bias was assessed using a tool designed for RCTs therefore it is possible that this assessment  
6 may not capture potential sources of bias associated with the observational methods used in  
7 this SR.  
8  
9  
10  
11  
12

13 Overall, the qualitative synthesis represents findings from 929 participants the largest to date,  
14 however the meta-analyses pertain to a small number of participants and only provide a  
15 preliminary indication of the pooled effect estimate of airflow. The meta-analyses involve  
16 few studies therefore heterogeneity is difficult to estimate and the accuracy of the  $I^2$  value is  
17 less certain. (70) The number of studies that fulfilled the review criteria was restricted by the  
18 need for baseline breathlessness measures. Some of the included studies (32, 51) did not  
19 report repeated measurements in a format suitable for meta-analysis necessitating statistical  
20 assumptions. (42)  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Implications for practice and further research**

30  
31  
32 Airflow is safe and should be used as an adjunct to treatment for breathlessness at rest in  
33 those who do not require oxygen-enriched air. **Clinicians should consider airflow an**  
34 **important intervention to use as part of a breathlessness management programme in**  
35 **breathlessness at rest irrespective of cause. The relief of breathlessness during exertion in**  
36 **those with COPD may provide a useful intervention during pulmonary rehabilitation where**  
37 **breathlessness is a reason for poor adherence.**  
38  
39  
40  
41  
42

43 The fan, when taught by an appropriately trained clinician, offers patients an inexpensive and  
44 portable source of airflow likely to benefit exertion-induced breathlessness. Recovery time  
45 from exertion induced breathlessness is an important patient-reported outcome and further  
46 work is needed to explore the role of airflow in recovery, self-efficacy and increased daily  
47 activity as part of complex breathlessness intervention programmes including rehabilitation.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Conclusion

These data support facial or nasal airflow for clinically meaningful relief of breathlessness at rest. This SR pulls together the growing evidence to support airflow as an effective self-management option for people with chronic breathlessness and identifies airflow as an intervention for future study.

## Declarations.

**Authorship:** Concept - FS; Design - FS, MJJ, CB, SB, JY; Data collection - FS, AN; Data analysis - FS, VA, MB; Data interpretation- All; Draft manuscript FS; critical revision of manuscript for intellectual content – All; approval final manuscript – All.

**Funding:** This study was funded as part of a University of Hull PhD studentship (Flavia Swan)

**Declaration of conflicts of interest:** The Authors declare that there is no conflict of interest.

**Data management and sharing:** The full search strategy is found in the Online Supplementary materials and included and excluded papers are presented.

## References

1. Currow DC, Dal Grande E, Ferreira D, Johnson MJ, McCaffrey N, Ekström M. Chronic breathlessness associated with poorer physical and mental health-related quality of life (SF-12) across all adult age groups. *Thorax*. 2017.
2. Smith AK, Currow DC, Abernethy AP, Johnson MJ, Miao Y, Boscardin WJ, et al. Prevalence and Outcomes of Breathlessness in Older Adults: A National Population Study. *Journal of the American Geriatrics Society*. 2016;64(10):2035-41.
3. Parshall MB. Adult Emergency Visits for Chronic Cardiorespiratory Disease: Does Dyspnea Matter? *Nurs Res*. 1999;48(2):62-70.
4. Parshall MB, Doherty GS. Predictors of emergency department visit disposition for patients with chronic obstructive pulmonary disease. *Heart & Lung: The Journal of Acute and Critical Care*. 35(5):342-50.
5. Hutchinson A, Pickering A, Williams P, Bland JM, Johnson MJ. Breathlessness and presentation to the emergency department: a survey and clinical record review. *BMC Pulmonary Medicine*. 2017;17:1-7.
6. Bausewein C, Booth S, Gysels M, Kuhnbach R, Haberland B, Higginson IJ. Understanding breathlessness: cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. *Journal of Palliative Medicine*. 2010;13(9):1109-18.
7. Booth S, Silvester S, Todd C. Breathlessness in cancer and chronic obstructive pulmonary disease: using a qualitative approach to describe the experience of patients and carers. *Palliative & Supportive Care*. 2003;1(4):337-44.
8. Williams V, Bruton A, Ellis-Hill C, McPherson K. What really matters to patients living with chronic obstructive pulmonary disease? An exploratory study. *Chronic Respiratory Disease*. 2007;4(2):77-85.
9. Johnson MJ, Yorke J, Hansen-Flaschen J, Lansing R, Ekström M, Similowski T, et al. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. *European Respiratory Journal*. 2017;49(5).
10. Farquhar MC, Prevost AT, McCrone P, Brafman-Price B, Bentley A, Higginson IJ, et al. The clinical and cost effectiveness of a Breathlessness Intervention Service for patients with advanced non-malignant disease and their informal carers: mixed findings of a mixed method randomised controlled trial. *Trials*. 2016;17(1):1-16.
11. Higginson IJ, Bausewein C, Reilly CC, Gao W, Gysels M, Dzingina M, et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. *The Lancet Respiratory Medicine*. 2014;2(12):979-87.
12. Barton R EA, Nabb S, Rigby AS, and Johnson MJ A randomised trial of high Vs low intensity training in breathing techniques for breathless patients with malignant lung disease: A feasibility study. *Lung cancer* 2010;70:313-9.
13. Johnson MJ, Booth S, Currow DC, Lam LT, Phillips JL. A Mixed-Methods, Randomized, Controlled Feasibility Trial to Inform the Design of a Phase III Trial to Test the Effect of the Handheld Fan on Physical Activity and Carer Anxiety in Patients With Refractory Breathlessness. *Journal of Pain and Symptom Management*. 2016;51(5):807-15.
14. Booth S, Galbraith S, Ryan R, Parker RA, Johnson M. The importance of the feasibility study: Lessons from a study of the hand-held fan used to relieve dyspnea in people who are breathless at rest. *Palliative Medicine*. 2016;30(5):504-9.
15. Swan F BS. The role of airflow for the relief of chronic refractory breathlessness. . *Current Opinion in Supportive & Palliative Care* 2015;Sept 9(3):206-11.
16. Bausewein C BS, Gysels M, Kuhnbach R, and Higginson I J,. Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial. *BMC Palliative Care* 2010;9(22).

17. Galbraith S, Fagan P, Perkins P, Lynch A, Booth S. Does the use of a handheld fan improve chronic dyspnea? A randomized, controlled, crossover trial. *Journal of Pain and Symptom Management* [Internet]. 2010; (5):[831-8 pp.].
18. Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold Facial Stimulation Reduces Breathlessness Induced in Normal Subjects. *American Journal of Respiratory and Critical Care Medicine*. 1987;136(1):58-61.
19. Liss HP GJ. The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. *American Review Respiratory disease* 1988;137:1285-8.
20. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, et al. An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea. *American Journal of Respiratory and Critical Care Medicine*. 2012;185(4):435-52.
21. Johnson MJ, Simpson MIG, Currow DC, Millman RE, Hart SP, Green G. Magnetoencephalography to investigate central perception of exercise-induced breathlessness in people with chronic lung disease: a feasibility pilot. *BMJ Open*. 2015;5(6):e007535.
22. Morélot-Panzini C. Fooling the brain to alleviate dyspnoea. *European Respiratory Journal*. 2017;50(2).
23. Lockett T PJ, Johnson MJ, Farquhar M, Swan F, Assen T, Bhattarai P, Booth S. . Contributions of a hand-held fan to self-management of chronic breathlessness. . *European Respiratory Journal*. 2017;50(1700262).
24. Mularski R, Reinke L, al C-KVe. An official American Thoracic Society workshop report: Assessment and palliative management of dyspnea crisis. *Annals American Thoracic Society*. 2013;10(5):S98-105.
25. Ben-Aharon I, Gafter-Gvili A, Paul M, Leibovici L, Stemmer SM. Interventions for Alleviating Cancer-Related Dyspnea: A Systematic Review. *Journal of Clinical Oncology*. 2008;26(14):2396-404.
26. Booth S, Wade R, Johnson M, Kite S, Swannick M, Anderson H, et al. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. *Respiratory Medicine*. 2004;98(1):66-77.
27. Cranston Josephine M, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. *Cochrane Database of Systematic Reviews* [Internet]. 2008; (3).
28. Uronis HE, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis. *Br J Cancer*. 2008;98(2):294-9.
29. Abernethy AP, McDonald CF, Frith PA, Clark K, Herndon JE, 2nd, Marcello J, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. *Lancet*. 2010;376(9743):784-93.
30. Bell EC, Cox NS, Goh N, Glaspole I, Westall GP, Watson A, et al. Oxygen therapy for interstitial lung disease: a systematic review. *European Respiratory Review*. 2017;26(143).
31. Ekstrom M, Ahmadi Z, Bornefalk-Hermansson A, Abernethy A, Currow D. Oxygen for breathlessness in patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. *Cochrane Database of Systematic Reviews*. 2016;11:CD006429.
32. Booth S, Kelly MJ, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer? *American Journal of Respiratory and Critical Care Medicine*. 1996;153(5):1515-8.
33. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. 2011. In: *The Cochrane Collaboration* [Internet]. Available from [www.handbook.cochrane.org](http://www.handbook.cochrane.org) .
34. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement 2009 2009-07-21 10:46:49.
35. Bausewein C, Booth S, Gysels M, Higginson Irene J. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. *Cochrane Database of Systematic Reviews* [Internet]. 2008; (2).

- 1
- 2
- 3
- 4 36. Royal College of Physicians. Domiciliary oxygen therapy services: clinical guidelines and
- 5 advice for prescribers. A report of the Royal College of Physicians. London: Royal College of
- 6 Physicians; 1999.
- 7 37. Uronis H, McCrory Douglas C, Samsa G, Currow D, Abernethy A. Symptomatic oxygen for
- 8 non-hypoxaemic chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews
- 9 [Internet]. 2011; (6).
- 10 38. Report of the medical research council working party. Long term domiciliary oxygen in
- 11 chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *Lancet*. 1981;1:681-
- 12 6.
- 13 39. Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies
- 14 2008.
- 15 40. Powers J, Bennett S. Measurement of dyspnea in patients treated with mechanical
- 16 ventilation. *American Journal of Critical Care*. 1999;8(4):254-61.
- 17 41. Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, et al. Studies
- 18 comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment
- 19 of pain intensity in adults: a systematic literature review. *J Pain Symptom Manage*. 2011;41(6):1073-
- 20 93.
- 21 42. Hozo S, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range,
- 22 and the size of a sample. *BMC Medical Research Methodology*. 2005;5(1):13.
- 23 43. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses
- 24 *The Cochrane Collaboration*, ; 2011. .
- 25 44. Wong SL, Leong SM, Chan CM, Kan SP, Cheng HW. The Effect of Using an Electric Fan on
- 26 Dyspnea in Chinese Patients With Terminal Cancer. *American Journal of Hospice & Palliative*
- 27 *Medicine*.34(1):42-6.
- 28 45. Eaton T, Fergusson W, Kolbe J, Lewis CA, West T. Short-burst oxygen therapy for COPD
- 29 patients: a 6-month randomised, controlled study. *European Respiratory Journal*. 2006;27(4):697-
- 30 704.
- 31 46. Eves ND, Sandmeyer LC, Wong EY, Jones LW, Macdonald GF, Ford GT, et al. Helium-
- 32 Hyperoxia: A Novel Intervention To Improve the Benefits of Pulmonary Rehabilitation for Patients
- 33 With COPD. *Chest*. 2009;135(3):609-18.
- 34 47. Jolly EC, Di Boscio V, Aguirre L, Luna CM, Berensztein S, Gené RJ. Effects of Supplemental
- 35 Oxygen During Activity in Patients With Advanced COPD Without Severe Resting Hypoxemia. *Chest*.
- 36 2001;120(2):437-43.
- 37 48. Marciniuk DD, Butcher SJ, Reid JK, MacDonald GF, Eves ND, Clemens R, et al. The Effects of
- 38 Helium-Hyperoxia on 6-mm Walking Distance in COPD: A Randomized, Controlled Trial. *CHEST*.
- 39 2007;131(6):1659-65.
- 40 49. McDonald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE. Exertional oxygen of limited
- 41 benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. *American*
- 42 *Journal of Respiratory and Critical Care Medicine* [Internet]. 1995; (5 Pt 1):[1616-9 pp.].
- 43 50. Moore RP, Berlowitz DJ, Denehy L, Pretto JJ, Brazzale DJ, Sharpe K, et al. A randomised trial
- 44 of domiciliary, ambulatory oxygen in patients with COPD and dyspnoea but without resting
- 45 hypoxaemia. *Thorax* [Internet]. 2011; (1):[32-7 pp.].
- 46 51. Philip J, Gold M, Milner A, Di Iulio J, Miller B, Spruyt O. A Randomized, Double-Blind,
- 47 Crossover Trial of the Effect of Oxygen on Dyspnea in Patients with Advanced Cancer. *Journal of Pain*
- 48 *and Symptom Management*. 2006;32(6):541-50.
- 49 52. Scorsone D, Bartolini S, Saporiti R, Braido F, Baroffio M, Pellegrino R, et al. Does a Low-
- 50 Density Gas Mixture or Oxygen Supplementation Improve Exercise Training in COPD? *Chest*.
- 51 2010;138(5):1133-9.
- 52 53. Wadell K, Henriksson-Larsen K, Lundgren R. Physical training with and without oxygen in
- 53 patients with chronic obstructive pulmonary disease and exercise-induced hypoxaemia. *Journal of*
- 54 *rehabilitation medicine*. 2001;33(5):200-5.
- 55
- 56
- 57
- 58
- 59
- 60



- 1
- 2
- 3
- 4 54. Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC. Clinically Important
- 5 Differences in the Intensity of Chronic Refractory Breathlessness. *Journal of Pain and Symptom*
- 6 *Management*. 2013;46(6):957-63.
- 7 55. Ries A. Minimally clinically important difference for the UCSD Shortness of Breath
- 8 Questionnaire, Borg Scale, and Visual Analog Scale. *Journal of Chronic Obstructive Pulmonary*
- 9 *Disease*. 2005;2:105-10.
- 10 56. Johnson MJ YJ, Hansen-Flaschen J, Lansing R, Ekstrom M, Similowski T, Currow D. . Towards
- 11 an expert consensus to delineate a clinical syndrome of chronic breathlessness. . *European*
- 12 *Respiratory Journal* 2017.
- 13 57. Lockett T, Phillips J, Johnson MJ, Farquhar M, Swan F, Assen T, et al. Contributions of a hand-
- 14 held fan to self-management of chronic breathlessness. *European Respiratory Journal*. 2017;50(2).
- 15 58. Currow DC, Abernethy AP, Johnson MJ. Activity as a Measure of Symptom Control. *Journal of*
- 16 *Pain and Symptom Management*. 2012;44(5):e1-e2.
- 17 59. Maddocks M, Taylor V, Klezlova R, England R, Manderson C, Wilcock A. When will I get my
- 18 breath back? Recovery time of exercise-induced breathlessness in patients with thoracic cancer.
- 19 *Lung cancer*. 2012;76(1):128-9.
- 20 60. Johnson MJ, Simpson M, Millman R, Green G. Magnetoencephalography as a neuro-imaging
- 21 method in chronic dyspnoea: A feasibility study. *European Respiratory Journal*. 2014;44(Suppl.
- 22 58):P670.
- 23 61. Baltzan MA, Alter A, Rotaple M, Kamel H, Wolkove N. Fan to palliative exercise-induced
- 24 dyspnoea with severe COPD. *Journal of respiratory and critical care medicine*. 2000;161(3
- 25 supplement):A59.
- 26 62. Marchetti N, Travaline J, Criner G. Air current applied to the face of COPD patients enhances
- 27 leg ergometry performance. *Am J Resp and Crit Care*. 2004;169:A773.
- 28 63. Resnick B SA. Understanding what motivates older adults to exercise *Journal of*
- 29 *gerontological nursing*. 2000;26(3):34-41.
- 30 64. Keating A, Lee A, Holland AE. What prevents people with chronic obstructive pulmonary
- 31 disease from attending pulmonary rehabilitation? A systematic review. *Chronic Respiratory Disease*.
- 32 2011;8(2):89-99.
- 33 65. Fischer MJ, Scharloo M, Abbink JJ, van 't Hul AJ, van Ranst D, Rudolphus A, et al. Drop-out
- 34 and attendance in pulmonary rehabilitation: The role of clinical and psychosocial variables.
- 35 *Respiratory Medicine*. 2009;103(10):1564-71.
- 36 66. Ries AL, Kaplan RM, Myers R, Prewitt LM. Maintenance after pulmonary rehabilitation in
- 37 chronic lung disease: a randomized trial. *Am J Respir Crit Care Med*. 2003;167(6):880-8.
- 38 67. Heppner PS, Morgan C, Kaplan RM, Ries AL. Regular walking and long-term maintenance of
- 39 outcomes after pulmonary rehabilitation. *Journal of Cardiopulmonary Rehabilitation*. 2006;26(1):44-
- 40 53.
- 41 68. Marchetti N, Lammi MR, Travaline JM, Ciccolella D, Civic B, Criner GJ. Air Current Applied to
- 42 the Face Improves Exercise Performance in Patients with COPD. *Lung*. 2015;193(5):725-31.
- 43 69. Farquhar MC, Prevost AT, McCrone P, Brafman-Price B, Bentley A, Higginson IJ, et al. Is a
- 44 specialist breathlessness service more effective and cost-effective for patients with advanced cancer
- 45 and their carers than standard care? Findings of a mixed-method randomised controlled trial. *BMC*
- 46 *Medicine*. 2014;12(1):194.
- 47 70. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in*
- 48 *Medicine*. 2002;21(11):1539-58.
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

**Online Supplementary Table 1 Full Search strategy**

1. *Exploded MeSH lung diseases obstructive*
2. *Exploded MeSH pulmonary disease, chronic obstructive*
3. *COPD key word*
4. *Exploded MeSH neoplasms*
5. *Exploded MeSH lung diseases, interstitial*
6. 1 OR 2 OR 3 OR 4 OR 5
7. *Exploded MeSH heart failure, congestive*
8. *MotorADJ1neuroneADJ1disease text word*
9. *Exploded amyotrophic lateral sclerosis*
10. *Kyphoscoliosis text word*
11. *Exploded MeSH pulmonary fibrosis*
12. 7 OR 8 OR 9 OR 10 OR 11 or / 1-5
13. *Hand-held fan OR fan text word*
14. *Medical ADJ1 air text word*
15. *Exploded MeSH oxygen inhalation therapy*
16. *AirADJ1flow text word*
17. *Facial OR nasal AND cold OR cooling text word*
18. 13 OR 14 OR 15 OR 16 OR 17
19. *Exploded MeSH Dyspnea*
20. *dyspnoea key word*
21. *Difficulty OR short ADJ1 breath\$ text word*
22. *Exploded MeSH Exercise*
23. *Exploded MeSH "Activities of Daily Living"*
24. 19 OR 20 OR 21 OR 22 OR 23
25. 12 AND 18 AND 24



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Online Supplementary Table 2 Risk of Bias. Methodological quality of included studies**

Study reference	Study author	Study design	Sequence generation	Allocation concealment	Blinding	Withdrawals, incomplete data	Selective outcome reporting	Free of other issues or bias
14	Booth (2016)	cohort	n/a	n/a	high	low	low	high
16	Bausewein (2010)	RCT	low	low	high	unclear	low	low
17	Galbraith (2010)	RCT	low	low	high	low	low	low
13	Johnson (2016)	RCT	low	low	high	low	low	low
44	Wong (2017)	RCT	unclear	unclear	high	low	low	low
29	Abernethy (2010)	RCT	low	low	low	low	low	low
32	Booth (1996)	RCT	low	low	low	low	low	unclear
45	Eaton (2006)	RCT	low	low	low	unclear	low	low
46	Eves (2009)	RCT	low	low	low	low	low	low
47	Jolly (2001)	RCT	unclear	unclear	low	low	low	unclear
48	Marciniuk (2007)	RCT	unclear	unclear	low	low	low	low
49	McDonald (1995)	RCT	unclear	unclear	low	low	low	unclear
50	Moore (2011)	RCT	low	low	low	low	low	low
51	Philip (2006)	RCT	unclear	unclear	unclear	low	low	low

52	Scorsone (2010)	RCT	unclear	unclear	low	low	low	low
53	Wadell (2001)	RCT	unclear	unclear	unclear	low	low	low

Codes: low = low risk of bias    unclear = unclear risk of bias    high = high risk of bias    n/a =not applicable

For Peer Review

**Online Supplementary Table 3 Characteristics of excluded studies (n=62)**

<b>Study</b>	<b>Reason</b>	<b>Study</b>	<b>Reason</b>
Ahmedzai et al (2004)	No repeat measures	Light et al (1989)	No repeat measures
Alison et al (2016)	Protocol only	Liss et al (1988)	Hypoxic
Arizono (2015)	Abstract poster only	Maltais et al (2001)	No repeat measures
Baltzan et al (2000)	No baseline measures	Marchetti et al (2015)	No baseline or repeat measures
Bruera et al (1992)	Participants hypoxic	Marques-Magallanes (1988)	Hypoxic
Bruera et al (1993)	Insufficient data, hypoxaemia	McKeon et al (1988)	No repeat measures
Breura et al (2003)	No repeated measures	Meecham Jones et al (1995)	No repeat measures
Bruni et al (2012)	No baseline measures	Miki et al (2012)	No baseline measures
Chua et al (1996)	No baseline measures	Moore et al (1992)	No baseline or repeat measures
Currow et al (2009)	No airflow arm	Moore et al (2009)	Participants hypoxic
Davidson et al (1988)	No baseline measures	Nandi et al (2003)	No repeat measures
Dean et al (1992)	No repeat measures	Neunhauserer (2016)	No dyspnoea outcome
Derry et al (2006)	No breathlessness score	Nishiyama et al (2013)	No repeat measures
Dyer et al (2012)	No airflow	Nonoyama (2007)	No repeat measures
Eaton et al (2002)	No repeat measures	O'Driscoll et al (2011)	No repeat measures
Emtner et al (2003)	No repeat measures	Oliveira (2012)	No airflow arm
Evans et al (1986)	No follow up measures	Ozalevli et al (2007)	Room air, but not airflow
Garrod et al (1999)	No follow up measures	Quantrill et al (2007)	No repeat measures
Garrod et al (2000)	Participants hypoxic	Restrck et al (1992)	No repeat measures
Haidl et al (2003)	No airflow for control group	Ringbaek et al (2013)	No dyspnoea outcome
Killen & Corris (2000)	No repeat measures	Rooyackers et al (1997)	No airflow arm

Koshy (2016)	No baseline measures	Russell et al (1999)	No repeat measures
Jarosch et al (2017)	No repeat measures	Sandland et al (2008)	Participants hypoxic
Knebel et al (2000)	No repeat measures	Sharma et al (2011)	Opinion piece
Koskela et al (1988)	Sub-zero temperature -20°C	Somfay et al (2001)	No repeat measures
Lacasse et al (2005)	Participants hypoxic	Spence et al. (1993)	Sub-zero temperature
Laude et al (2006)	No repeat measures	Spielmanns (2015)	No dyspnoea outcome
Leach et al (1992)	No repeat measures	Stevenson et al (2004)	No repeat measures
Lellouche (2016)	No dyspnoea outcome	Swinburn et al (1991)	Participants hypoxic
Lewis et al (2003)	No repeat measures	Troy et al (2014)	Abstract poster only
Lewis et al (2003)	No repeat measures	Woodcock et al (1981)	No repeat measures

**eAppendix 1 References to excluded studies**

Ahmedzai SH, Laude E, Robertson A, Troy G, Vora V. A double-blind, randomised, controlled phase II trial of Heliox28 gas mixture in lung cancer patients with dyspnoea on exertion. *British Journal of Cancer* 2004; 90: 366–71.

Alison et al, A randomised controlled trial of supplemental oxygen versus medical air during exercise training in people with chronic obstructive pulmonary disease: supplemental oxygen in pulmonary rehabilitation trial (SuppORT) (Protocol) *BMC Pulmonary Medicine* 2016; 16: 25

Arizono S, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, et al. Benefits of supplemental oxygen on exercise capacity in IPF patients with exercise-induced hypoxemia. *European Respiratory Journal*. 2015; Vol. 46, issue S59:OA4971

Baltzan MA, Alter A, Rotaple M, Kamel H, Wolkove N. Fan to palliative exercise-induced dyspnoea with severe COPD. *American Journal of Respiratory and Critical Care Medicine* 2000; 161 (3 Suppl): A59.

Bruera E, Sweeney C, Willey J, Palmer JL, Strasser F, Morice RC, et al A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. *Palliative Medicine* 2003; 17: 659–63.

Bruera E, Schoeller T, MacEachern T. Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomized controlled trial. *Journal of Pain and Symptom Management* 1992; 7 (6):365–8.

Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. *Lancet* 1993; 342 (8862):13–4.

Bruni GI, Gigliotti F, Binazzi B, Romagnoli I, Duranti R, Scano G. Dyspnea, chest wall hyperinflation, and rib cage distortion in exercising patients with chronic obstructive pulmonary disease. *Medicine and Science in Sports and Exercise* 2012;44 (6):1049-56.

Chua TP, Ponikowski PP, Harrington D, Chambers J, Coats AJ. Contribution of peripheral chemoreceptors to ventilation and the effects of their suppression on exercise tolerance in chronic heart failure. *Heart* 1996; 76 (6):483–9.

Currow D, Smith J, and Abernethy A, Does palliative home oxygen improve dyspnoea? A consecutive cohort study *Palliative Medicine* 2009; 23: 309-316.

Davidson AC, Leach R, George RJD, Geddes DM. Supplemental oxygen and exercise ability in chronic obstructive pulmonary disease. *Thorax* 1988; 43: 965–71.

Dean NC, Brown JK, Himelman RB, Doherty JJ, Gold WM, Stulbarg MS. Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia. *American Review of Respiratory Disease* 1992; 146: 941–5.

Derry D, Madsen C, Rossdale M, et al Use of a handheld fan and face-wipe speeds resolution of breathlessness in patients with chronic obstructive pulmonary disease but does not improve exercise capacity *European Respiratory Journal* 2006; 28 Suppl 50: 71s

Dyer F, Callaghan J, Cheema K, and Bott J. Ambulatory oxygen improves the effectiveness of pulmonary rehabilitation in selected patients with chronic obstructive pulmonary disease *Chronic Respiratory Disease* 2012; 9; (2) 83-91.

Eaton T, Garret JE, Young P, Fergusson W, Kolbe J, Rudkin S, et al. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. *European Respiratory Journal* 2002; 20 (2):306–12.

- 1  
2  
3 Emtner M, Porszasz J, Burns M, Somfay A, Casaburi R. Benefits of supplemental oxygen in  
4 exercise training in nonhypoxemic chronic obstructive pulmonary disease patients.  
5 *American Journal of Respiratory and Critical Care Medicine* 2003; 168 (9):1034–42.
- 6 Evans TW, Waterhouse JC, Carter A, Nicholl JF, Howard P. Short burst oxygen treatment for  
7 breathlessness in chronic obstructive airways disease. *Thorax* 1986; 41: 611–5.
- 8 Garrod R, Bestall JC, Paul E, Wedzicha JA. Evaluation of pulsed dose oxygen delivery during  
9 exercise in patients with severe chronic obstructive pulmonary disease. *Thorax* 1999; 54  
10 (3):242–4.
- 11 Garrod R, Paul EA, Wedzicha JA. Supplemental oxygen during pulmonary rehabilitation in  
12 patients with COPD with exercise hypoxaemia. *Thorax* 2000; 55: 539–43.
- 13 Jarosch 2017
- 14 Kosela H, Pihlajamaki J, Pekkarinen H et al Effect of cold air on exercise capacity in COPD:  
15 increase or decrease? *Chest* 1988; 113: (6) 1560-1565.
- 16 Koshy A, Pellicori P, Clark AL. The effect of increasing inspired oxygen on exercise  
17 performance in patients with chronic heart failure *Heart* 2016; 102: (8) 597-601
- 18 Killen JWW, Corris PA. A pragmatic assessment of the placement of oxygen when given for  
19 exercise induced dyspnea. *Thorax* 2000; 55: 544–6.
- 20 Knebel AR, Bentz E, Barnes P. Dyspnea management in alpha-1 antitrypsin deficiency: effect  
21 of oxygen administration. *Nursing Research* 2000; 49 (6):333–8.
- 22 Lacasse Y, Lecours R, Pelletier C, et al. randomised trial of ambulatory oxygen in oxygen-  
23 dependent COPD *European Respiratory Journal* 2005; 25: 1032-1038.
- 24 Laude EA, Duffy NC, Baveystock C, Dougill B, Campbell MJ, Lawson R, et al. The effect of  
25 helium and oxygen on exercise performance in chronic obstructive pulmonary disease.  
26 *American Journal of Respiratory and Critical Care Medicine* 2006; 173 (8):865–70.
- 27 Leach RM, Davidson AC, Chinn S, Twort CHC, Cameron IR, Bateman NT. Portable liquid  
28 oxygen and exercise ability in severe respiratory disability. *Thorax* 1992; 47: 781–9.
- 29 Lellouche F, L'Her E, Bouchard PA, Brouillard C, Maltais F, Automatic Oxygen Titration During  
30 Walking in Subjects With COPD: A Randomized Crossover Controlled Study 2016 *Respiratory*  
31 *Care* 2016; 61 (11): 1456-1464
- 32 Lewis CA, Eaton TE, Young P, Kolbe J. Short-burst oxygen immediately before and after  
33 exercise is ineffective in nonhypoxic COPD patients. *European Respiratory Journal* 2003; 22  
34 (4):584–8.
- 35 Light RW, Mahutte CK, Stansbury DW, Fischer CE, Brown SE. Relationship between  
36 improvement in exercise performance with supplemental oxygen and hypoxic ventilatory  
37 drive in patients with chronic airflow obstruction. *Chest* 1989; 95: 751–6.
- 38 Liss HP, Grant BJB. The effect of nasal flow on breathlessness in patients with chronic  
39 obstructive pulmonary disease. *American Review of Respiratory Disease* 1988; 137: 1285–8.
- 40 Maltais F, Simon M, Jobin J, Desmeules M, Sullivan M, Belanger M, et al. Effects of oxygen  
41 on lower limb blood flow and O<sub>2</sub> uptake during exercise in COPD. *Medicine and Science in*  
42 *Sports and Exercise* 2001; 33 (6): 916–22.
- 43 Marchetti N, Lammi M R, Travaline JM, Ciccolella D, Civic, B, Criner GJ, Air Current Applied to  
44 the Face Improves Exercise Performance in Patients with COPD *Lung* 2015; 193 (5): 725-31
- 45 Marques-Magallanes JA, Storer TW, Cooper CB. Treadmill exercise duration and dyspnea  
46 recovery time in chronic obstructive pulmonary disease: effects of oxygen breathing and  
47 repeated testing. *Respiratory Medicine* 1998; 92: 735–8.
- 48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 Miki K, Maekura R, Hiraga T, Kitada S, Miki M, Yoshimura K, et al. Effects of oxygen on  
4 exertional dyspnoea and exercise performance in patients with chronic obstructive  
5 pulmonary disease. *Respirology (Carlton, Vic)* 2012;**17**(1):149-54.
- 6 McKeon JL, Murree-Allen K, Saunders NA. Effects of breathing supplemental oxygen before  
7 progressive exercise in patients with chronic obstructive lung disease. *Thorax* 1988; 43 (1):  
8 53–6.
- 9  
10 Meecham Jones DJ, Paul EA, Bell JH, Wedzicha JA. Ambulatory oxygen therapy in stable  
11 kyphoscoliosis. *European Respiratory Journal* 1995; 8 (5) 819–23.
- 12 Moore D, Weston A, Hughes J et al Effects of inspired oxygen concentrations on exercise  
13 performance in chronic heart failure. *The Lancet* 1992; 339 (8797) 850-853.
- 14 Moore R, Berlowitz D, Pretto J et al Acute effects of hyperoxia on resting pattern of  
15 ventilation and dyspnoea in COPD. *Respirology* 2009; 14 (4) 545-50.
- 16 Nandi K, Smith AA, Crawford A, MacRae KD, Garrod R, Seed WA, et al. Oxygen  
17 supplementation before or after submaximal exercise in patients with chronic obstructive  
18 pulmonary disease. *Thorax* 2003; 58: 670–3.
- 19 Neunhauserer D et al, Supplemental Oxygen During High-Intensity Exercise Training in  
20 Nonhypoxemic Chronic Obstructive Pulmonary Disease *American Journal of Medicine* 2016;  
21 129 (11): 1185-1193
- 22  
23 Nishiyama O, Miyajima H, Fukai Y, Yamazaki R, Satoh R, Yamagata T, et al. Effect of  
24 ambulatory oxygen on exertional dyspnoea in IPF patients without resting hypoxemia.  
25 *Respiratory Medicine* 2013;**107**(8):1241-6.
- 26 Nonoyama M, brooks D, Guyatt G, and Goldstein R. Effect of oxygen on health quality of life  
27 in patients with Chronic Obstructive Pulmonary Disease with transient exertional hypoxemia  
28 *American journal of resp and critical care medicine* 2007; 176: 343-349
- 29 O’ Driscoll B, Neill J, Siddiq P, and Turkington P. A crossover study of short burst oxygen  
30 therapy (SBOT) for the relief of exercise-induced breathlessness in severe COPD. *BMC*  
31 *pulmonary medicine* 2011; 11 (23)
- 32 Oliveira MF, Rodrigues MK, Treptow E, Cunha TM, Ferreira EM, Neder JA. Effects of oxygen  
33 supplementation on cerebral oxygenation during exercise in chronic obstructive pulmonary  
34 disease patients not entitled to long-term oxygen therapy. *Clinical Physiology and Functional*  
35 *Imaging* 2012;**32**(1):52-8.
- 36 Ozalevli S, Ozden A, Gocen Z et al, Comparison of six minute walking tests with and without  
37 supplemental oxygen in obstructive pulmonary disease and exercise-induced oxygen  
38 desaturation *Annals of Saudi Medicine* 2007; 27: 92) 94-100.
- 39  
40 Quantrill S, White R, Crawford A, et al. Short burst oxygen therapy after activities of daily  
41 living in the home in Chronic Obstructive Pulmonary Disease *Thorax* 2007; 62: 702-705.
- 42 Restrck LJ, Davies SW, Noone L, Wedzicha JA. Ambulatory oxygen in chronic heart failure.  
43 *Lancet* 1992; 340 (8829):1192–3.
- 44 Rooyackers JM, Dekhuijzen PNR, Van Herwaarden CLA, Folgering HTM. Training with  
45 supplemental oxygen in patients with COPD and hypoxaemia at peak exercise. *European*  
46 *Respiratory Journal* 1997; 10 (6):1278–84.
- 47  
48 Ringbaek T, Martinez G, Lange P. The long-term effect of ambulatory oxygen in  
49 normoxaemic COPD patients: a randomised study. *Chronic Respiratory Disease* 2013;10  
50 (2):77-84.
- 51  
52 Russell SD, Koshkarian GM, Medinger AE, Carson PE, Higginbotham MB. Lack of effect of  
53 increased inspired oxygen concentrations on maximal exercise capacity or ventilation in  
54 stable heart failure. *American Journal of Cardiology* 1999; 84 (12):1412–6.
- 55  
56  
57  
58  
59  
60

- 1  
2  
3 Sandland CJ, Morgan MD, Singh SJ. Patterns of domestic activity and ambulatory oxygen  
4 usage in COPD. *Chest* 2008; 134 (4):753–60.
- 5 Sharma U, Ewigman B, Diving for PURLS. Pressurized oxygen and room air have similar  
6 benefit in refractory dyspnea. *Evidence-based Practice* 2011; 14: 92) 4.
- 7 Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation  
8 and exercise endurance in non-hypoxemic COPD patients. *European Respiratory Journal*  
9 2001; 18 (1): 77–84.
- 10  
11 Spence D, Graham D, Ahmed J, et al. Does cold air affect exercise capacity and dyspnea in  
12 stable chronic obstructive pulmonary disease? *Chest* 1993; 103: (3) 693—696
- 13 Spielmanns M, Fuchs-Bergsma C, Winkler A, Fox G, Krüger S, Baum K. Effects of oxygen  
14 supply during training on subjects with COPD who are normoxemic at rest and during  
15 exercise: a blinded randomized controlled trial. *Respiratory Care* 2015;60:540-8.
- 16 Stevenson NJ, Calverley PM. Effect of oxygen on recovery from maximal exercise in patients  
17 with chronic obstructive pulmonary disease. *Thorax* 2004; 59: 668–72.
- 18 Swinburn CR, Mould H, Stone TN, Corris PA, Gibson GJ. Symptomatic benefit of  
19 supplemental oxygen in hypoxemic patients with chronic lung disease. *American Review of*  
20 *Respiratory Disease* 1991; 143: 913–5.
- 21  
22 Troy L, Young I, Munoz P, Taylor N, Webster S, Lau E, et al. Does supplemental oxygen  
23 increase exercise endurance in patients with idiopathic pulmonary fibrosis?. *Respirology*.  
24 2014; Vol. 19:95.
- 25  
26 Voduc N, Tessier C, Sabri E, Fergusson D, Lavallee L, Aaron SD. Effects of oxygen on exercise  
27 duration in chronic obstructive pulmonary disease patients before and after pulmonary  
28 rehabilitation. *Canadian Respiratory Journal [Revue canadienne de pneumologie]*  
29 2010;17(1):e14-e9.
- 30 Woodcock AA, Gross ER, Geddes DM. Oxygen relieves breathlessness in “pink puffers”.  
31 *Lancet* 1981; 1 (8226): 907–9.
- 32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review




Figure 2 Meta-analysis of fan at rest

193x42mm (96 x 96 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 3 Meta-analysis of cylinder air at rest

193x38mm (96 x 96 DPI)




Figure 4 Meta-analysis of cylinder medical air for exertion-induced breathlessness

203x38mm (96 x 96 DPI)



**PALLIATIVE MEDICINE AUTHOR SUBMISSION CHECKLIST**

Please complete this checklist for all papers submitted. Please indicate, very briefly, how this has been addressed. This checklist is a mandatory upload on submission.

Item	Explanation	How this has been addressed (briefly, a sentence will suffice)
Article title	<p><b>WHY: Because we want readers to find your work.</b>                      Have you followed our guidelines on writing a good title that will be found by search engines? (E.g. with methods in the title, use of common words for the issue addressed, no country names, and possibly indicating findings). If your study has an acronym is it included in the title?</p>	<p>We have indicated that we have found benefit from airflow and included the methodology in the title</p>
Abstract	<p><b>WHY: Because structured abstracts have more detail for readers and search engines.</b>                      Have you followed our guidelines on writing your structured abstract? Please remember we have separate abstract structures for original research, reviews and case reports. There should be <b>no</b> abbreviations in the abstract, EXCEPT a study acronym which should be included if you have one. If a trial (or other design formally registered with a database) have you included your registration details?</p>	<p>We have written a structured abstract. The protocol was not registered with PROSPERO</p>
Key statements	<p><b>WHY: Because readers want to understand your paper quickly.</b>                      Have you included our key statements within the body of your paper (after abstract and before the main text is a good place!) and followed our guidelines for how these are to be written? There are three main headings required, and each may have 1-3 separate <b>bullet</b> points. Please use clear, succinct, single sentence separate bullet points rather than complex or multiple sentences.</p>	<p>These have been included</p>
Keywords	<p><b>WHY: Because MeSH headings mean it is properly indexed.</b>                      Have you given keywords for your study? We ask that these are current <b>MeSH</b> headings unless there is no suitable heading for use (please give explanation in cover letter). <a href="https://meshb.nlm.nih.gov/search">https://meshb.nlm.nih.gov/search</a></p>	<p>We have used MeSH headings with the addition of freetext for airflow as this is the topic of the paper and in the title</p>
International relevance	<p><b>WHY: We have readers from around the world who are interested in your work.</b>                      Have you contextualised your work for an international audience and explained how your work contributes to an international knowledge base? Avoid drawing from policy from one context only, think how your work could be relevant more widely. Do define terms clearly e.g. hospice has a different</p>	<p>This systematic review draws on papers from around the world</p>

	meaning in many countries.	
Publishing guidelines	<b>WHY: Because clear and robust reporting helps people interpret your work accurately</b> Have you submitted a completed checklist for a relevant publishing guideline as a supplementary file? <a href="http://www.equator-network.org/">http://www.equator-network.org/</a> These include CONSORT, PRISMA, COREQ checklists, but others may be more relevant for your type of manuscript. If no published checklist exists please create one as a table from the list of requirements in your chosen guideline. If your study design does not have a relevant publishing guideline please review closest matches and use the most appropriate with an explanation.	Yes (PRISMA)
Word count	<b>WHY: Because readers want to find the core information quickly.</b> Does your paper adhere to our word count for your article type? Please insert number of words in the box to the right. Remember that tables, figures, qualitative data extracts and references are not included in the word count.	4,422
Figures and tables and/or quotations	<b>WHY: Because readers want to find the core information quickly.</b> Have you adhered to our guidelines on the number of tables and figures for your article type?  Data (e.g. quotations) for qualitative studies are not included in the word count, and we prefer that they are integrated into the text (e.g. not in a separate table).	Yes
Study registration	<b>WHY: Because this means readers understand how you planned your study</b> Where appropriate have you included details (including reference number, date of registration and URL) of study registration on a database e.g. trials or review database. If your study has a published protocol, is this referenced within the paper?	Not applicable
Other study publications?	<b>WHY: So readers can understand the full context of your study</b> If there are other publications from this study are these referenced within the body of the paper? Please do not reference papers in preparation or submitted, but in-press publications are acceptable.	No
Scales, measures or questionnaires	<b>WHY: So readers can understand your paper in the context of this information</b> If your study primarily reports the development or testing of scales/measures or questionnaires have you included a copy of the instrument as a supplementary file?	Not applicable

Abbreviations	<b>WHY: Because abbreviations make a paper hard to read, and are easily misunderstood</b> Have you removed <b>all</b> abbreviations from the text except for extremely well known, standard abbreviations (e.g. SI units), which should be spelt out in full first? We do not allow abbreviations for core concepts such as palliative or end of life care.	We have kept the well-known abbreviations for ease of reading
Research ethics and governance approvals for research involving human subjects	<b>WHY: We will only publish ethically conducted research, approved by relevant bodies</b> Have you given full details of ethics/governance/data protection approvals with reference numbers, full name of the committee(s) giving approval and the date of approval? If such approvals are not required have you made it explicit within the paper why they were not required. Are details of consent procedures clear in the paper?	Not applicable
Date(s) of data collection	<b>WHY: So readers understand the context within which data were collected</b> Have you given the dates of data collection for your study within the body of your text? If your data are over 5 years old you will need to articulate clearly why they are still relevant and important to current practice.	yes
Structured discussion	<b>WHY: So readers can find key information quickly</b> Papers should have a structured discussion, with sub headings, summarising the main findings, addressing strengths and limitations, articulating what this study adds with reference to existing international literature, and presenting the implications for practice.	yes
Case reports	<b>WHY: So that participants are protected, and its importance made clear</b> If your study is a case report have you followed our clear structure for a case report, including highlighting what research is needed to address the issue raised? Have you made clear what consent was required or given for the publication of the case report? Have you provided evidence of such consent as a supplementary file to the editor?	Not applicable
Acknowledgements and declarations	<b>WHY: So readers understand the context of the research</b> Have you included a funding declaration according to the SAGE format? Are there acknowledgements to be made? Have you stated where data from the study are deposited and how they may be available to others? Have you conflicts of interest to declare?	Yes
Supplementary	<b>WHY: So the context is clear, but the main paper succinct for the reader</b>	We have provided supplementary

data and materials	Is there any content which could be provided as supplementary data which would appear only in the online version of accepted papers? This could include large tables, full search strategies for reviews, additional data etc.	details to ensure the reader has access to these
References	<b>WHY: So people can easily find work you have referenced</b> Are your references provided in SAGE Vancouver style? You can download this style within Endnote and other referencing software.	yes
Ownership of work.	Can you assert that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.	Yes





# PRISMA–DTA Checklist

Section/topic	#	PRISMA-DTA Checklist Item	Reported on page #
<b>TITLE / ABSTRACT</b>			
Title	1	Identify the report as a systematic review (+/- meta-analysis) of diagnostic test accuracy (DTA) studies.	1
Abstract	2	Abstract: See PRISMA-DTA for abstracts.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Clinical role of index test	D1	State the scientific and clinical background, including the intended use and clinical role of the index test, and if applicable, the rationale for minimally acceptable test accuracy (or minimum difference in accuracy for comparative design).	
Objectives	4	Provide an explicit statement of question(s) being addressed in terms of participants, index test(s), and target condition(s).	5
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (participants, setting, index test(s), reference standard(s), target condition(s), and study design) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	8
Search	8	Present full search strategies for all electronic databases and other sources searched, including any limits used, such that they could be repeated.	8 and online Table 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Definitions for data extraction	11	Provide definitions used in data extraction and classifications of target condition(s), index test(s), reference standard(s) and other characteristics (e.g. study design, clinical setting).	8
Risk of bias and applicability	12	Describe methods used for assessing risk of bias in individual studies and concerns regarding the applicability to the review question.	8
Diagnostic accuracy measures	13	State the principal diagnostic accuracy measure(s) reported (e.g. sensitivity, specificity) and state the unit of assessment (e.g. per-patient, per-lesion).	
Synthesis of results	14	Describe methods of handling data, combining results of studies and describing variability between studies. This could include, but is not limited to: a) handling of multiple definitions of target condition. b) handling of multiple thresholds of test positivity, c) handling multiple index test readers, d) handling of indeterminate test results, e) grouping and comparing tests,	9



# PRISMA–DTA Checklist

f) handling of different reference standards

Page 1 of 2

Section/topic	#	PRISMA-DTA Checklist Item	Reported on page #
Meta-analysis	D2	Report the statistical methods used for meta-analyses, if performed.	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	9
<b>RESULTS</b>			
Study selection	17	Provide numbers of studies screened, assessed for eligibility, included in the review (and included in meta-analysis, if applicable) with reasons for exclusions at each stage, ideally with a flow diagram.	9-10
Study characteristics	18	For each included study provide citations and present key characteristics including: a) participant characteristics (presentation, prior testing), b) clinical setting, c) study design, d) target condition definition, e) index test, f) reference standard, g) sample size, h) funding sources	Table 1
Risk of bias and applicability	19	Present evaluation of risk of bias and concerns regarding applicability for each study.	Online Table 2 and page 20
Results of individual studies	20	For each analysis in each study (e.g. unique combination of index test, reference standard, and positivity threshold) report 2x2 data (TP, FP, FN, TN) with estimates of diagnostic accuracy and confidence intervals, ideally with a forest or receiver operator characteristic (ROC) plot.	
Synthesis of results	21	Describe test accuracy, including variability; if meta-analysis was done, include results and confidence intervals.	21-22
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression; analysis of index test: failure rates, proportion of inconclusive results, adverse events).	
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence.	Beginning of discussion page 23, and conclusion page 25
Limitations	25	Discuss limitations from included studies (e.g. risk of bias and concerns regarding applicability) and from the review process (e.g. incomplete retrieval of identified research).	Page 24-25



# PRISMA–DTA Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Conclusions	26	Provide a general interpretation of the results in the context of other evidence. Discuss implications for future research and clinical practice (e.g. the intended use and clinical role of the index test).	Discussion 23 - 25
<b>FUNDING</b>			
Funding	27	For the systematic review, describe the sources of funding and other support and the role of the funders.	Page 26

*Adapted From:* McInnes MDF, Moher D, Thoms BD, McGrath TA, Bossuyt PM, The PRISMA-DTA Group (2018). Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. JAMA. 2018 Jan 23;319(4):388-396. doi: 10.1001/jama.2017.19163.

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

For Peer Review